2019 ANNUAL MEETING
GENOA, ITALY • 22-25 JUNE
CENTRO CONGRESSI – PORTO ANTICO DI GENOVA

PROGRAM
Welcome ................................................. 3
Leadership and Program Organizers .......... 4
Membership Information .......................... 6
About the Society ...................................... 7
Past Meetings .......................................... 8
Convention Centre Floor Plan ................. 9
Program At A Glance ................................ 10
General Information ................................. 12
Acknowledgments ..................................... 14
Individual Meetings ................................ 16

PROGRAM

SATURDAY
Education Course .................................... 18
Welcome Reception ................................... 21

SUNDAY
Kedrion Symposium ................................. 22
Pfizer Symposium ..................................... 22
Plenary Session: Peter J Dyck Lecture ....... 23
Platform Session I ................................. 23
Plenary Session: Richard Bunge Lecture ..... 24
Oral Poster Session I .............................. 24
Lunch & Poster Session I ......................... 25
Special Interest Group Parallel Sessions:
  Inflammatory Neuropathy
    Consortium (INC) ............................... 25
  Charcot-Marie-Tooth and Related
    Neuropathy Consortium (CMTR) .......... 27
International Diabetes Neuropathy
  Consortium (IDNC) ............................. 29
CSL Behring Symposium .......................... 31
Alnylam Symposium ............................... 31
Junior Reception ................................... 32

MONDAY
Takeda Symposium .................................. 33
Pharnext Symposium ................................ 33
Plenary Session: Arthur K Asbury Lecture ... 34
Platform Session II .................................. 34
Plenary Session: Jack Griffin Lecture ....... 35
Oral Poster Session II ............................. 35
PNS Annual General Meeting .................... 36
Lunch & Poster Session II ....................... 36
Special Interest Group Parallel Sessions:
  Inflammatory Neuropathy
    Consortium (INC) ............................... 36
  Charcot-Marie-Tooth and Related
    Neuropathy Consortium (CMTR) .......... 38
International Diabetes Neuropathy
  Consortium (IDNC) ............................. 40
Toxic Neuropathy Consortium (TNC) .......... 41
Grifols Symposium ............................... 43
Akcea Symposium .................................. 43

TUESDAY
LFB Symposium ...................................... 44
Plenary Session: PK Thomas Lecture ........ 44
Platform Session III ............................... 45
Plenary Session: Pembroke Lecture .......... 45
Oral Poster Session III ......................... 46
Lunch & Poster Session III ...................... 46
Clinical Trial Updates ............................ 47
Plenary Session: Presidential Lecture ....... 48
Awards & Prizes .................................... 48
Closing Reception .................................. 48
Exhibitor Directory ............................... 50

The PNS Annual Meeting continues to be the premier venue for learning about advances in peripheral neuropathy and peripheral nerve biology. The Program Committee has organized a spectacular meeting: the traditional mixture of carefully selected plenary lectures, oral platforms, oral posters, and poster sessions, as well as expanded symposia that were organized by the special interest groups — Charcot-Marie-Tooth and Related Neuropathies Consortium (CMTR), the Inflammatory Neuropathy Consortium (INC), the International Diabetes Neuropathy Consortium (IDNC), and the Toxic Neuropathy Consortium (TNC). We will also continue the innovative clinical trials session on Tuesday afternoon.

The local organizing committee and the PNS team have worked hard to enable the PNS to enjoy the beautiful and historic city of Genoa.

- On Saturday night, please join us for the Opening Reception at the Carlo Felice Theatre. The reception will feature classical music performed by the Genoa music conservatory, traditional Italian food, and drinks.
- On Sunday night, all are invited, as we honor Junior and new members of the Society with a reception at the Aquarium of Genoa. Sponsored by Akcea, this reception will feature guided exhibits, food, and beverages.
- On Tuesday night, please join us for a spectacular PNS Closing Reception at the beautiful Villa Lo Zerbino. Transportation will be provided to and from the Convention Centre. This event should not be missed!

Coffee breaks and lunch will be provided daily for delegates. Please see the program for additional details. Complimentary WiFi will also be provided (instructions can be found on page 12 of the program).

All are encouraged to attend the PNS Annual General Meeting on Monday, 24 June at 12.30. Your input is valuable, as we review the business of the PNS.

I want to personally thank our sponsors, the Scientific Program Committee, PNS Board, meeting faculty, staff, and everyone who has generously donated their time and efforts to put together this outstanding meeting. We sincerely hope you enjoy the 2019 PNS Annual Meeting and your stay in Italy.

Steven S. Scherer, MD, PhD
President, Peripheral Nerve Society
OFFICERS
Steven S. Scherer, MD, PhD, President, The University of Pennsylvania, Philadelphia, PA, USA
Pieter Van Doorn, MD, President-Elect, Erasmus MC University Medical Center, Rotterdam, Netherlands
Michael Polydefkis, MD, MHS, Secretary/Treasurer, Johns Hopkins Medicine, Baltimore, MD, USA
Mary M. Reilly, MD, FRCP, FRCPI, Past President, UCL Institute of Neurology, London, UK

BOARD MEMBERS
David Adams, MD, Hopital Bicetre, Hopitaux Universitaires, Le Kremlin Bicetre, France
Alessandra Bolino, PhD, Co-Chair, Scientific Program Committee, San Raffaele Hospital, Milan, Italy
Chiara Briani, MD, University of Padova, Padova, Italy
Satoshi Kuwabara, MD, Chiba University, Chiba, Japan
Ingemar Merkies, MD, St. Elisabeth Hospital, Curacao, Netherlands
Kazim Sheikh, MD, McGovern Medical School, Houston, TX, USA

INFLAMMATORY NEUROPATHY CONSORTIUM REPRESENTATIVE
Richard Lewis, MD, Cedars-Sinai, Los Angeles, CA, USA

CHARCOT-MARIE-TOOTH AND RELATED NEUROPATHIES CONSORTIUM REPRESENTATIVE
Davide Pareyson, MD, Carlo Besta Neurologic Institute, Milan, Italy

TOXIC NEUROPATHY CONSORTIUM REPRESENTATIVE
Guido Cavaletti, MD, University of Milano-Bicocca, Monza (l), Milan, Italy

INTERNATIONAL DIABETES NEUROPATHY CONSORTIUM REPRESENTATIVE
Christopher Gibbons, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

JPNS EDITOR
David Cornblath, MD, Johns Hopkins University, Baltimore, MD, USA

SCIENTIFIC PROGRAM COMMITTEE
Alessandra Bolino, PhD, Co-Chair, San Raffaele Hospital, Milan, Italy
John Svaren, PhD, Co-Chair, University of Wisconsin, Madison, Wisconsin, USA
Chiara Briani, MD, University of Padova, Padova, Italy
Guido Cavaletti, MD, University of Milano-Bicocca, Monza (l), Milan, Italy
Jerome Devaux, PhD, Institut de Neurosciences de Montpellier, Montpellier, France
Vera Fridman, MD, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Christopher Gibbons, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Ahmet Hoke, MD, PhD, Johns Hopkins Medicine, Baltimore, MD, USA
Giuseppe Lauria, MD, Carlo Besta Neurologic Institute, Milan, Italy
Davide Pareyson, MD, Carlo Besta Neurologic Institute, Milan, Italy
Amanda Peltier, MD, Vanderbilt University, Brentwood, TN, USA
Michael Polydefkis, MD, MHS, Johns Hopkins Medicine, Baltimore, MD, USA
Luis Querol, MD, PhD, Hospital de Sant Pau, Barcelona, Spain
Mary Reilly, MD, UCL Institute of Neurology, London, UK
Steven Scherer, MD, PhD, The University of Pennsylvania, Philadelphia, PA, USA
Nortina Shahrizaila, PhD, University of Malaya, Kuala Lumpur, Malaysia
Gordon Smith, MD, FAAN, Virginia Commonwealth University, Richmond, VA, USA
Charlotte Sumner, MD, John Hopkins Medicine, Baltimore, MD, USA
Pedro Tomaselli, MSc, Clinical Hospital of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
Pieter Van Doorn, MD, PhD, Erasmus MC University Medical Center, Rotterdam, Netherlands
LOCAL ORGANIZING COMMITTEE
Eduardo Nobile-Orazio, MD, PhD, Co-Chair, Milan University, Milan, Italy
Angelo Schenone, PhD, Co-Chair, University of Genoa, Italy
Luana Benedetti, MD, University of Genoa, Genoa, Italy
Marina Grandis, MD, University of Genoa, Genoa, Italy
Gianluigi Mancardi, PhD, President, Italian Society of Neurology, Genoa, Italy
Lucilla Nobbio, University of Genoa, Genoa, Italy

JUNIOR COMMITTEE
Vera Fridman, MD, Chair, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Pedro Tomasellli, MSc, Chair-Elect, Clinical Hospital of Ribeirão Preto, São Paulo, Brazil
Cervellini, Oxford, PhD, University of Oxford, Oxford, UK
Rhona McGonigal, PhD, University of Glasgow, Glasgow, UK
Oranne Sanmaneechai, MD, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Amro Stino, MD, Ohio State University, Columbus, OH, USA
Yuzhong Wang, MD, Affiliated Hospital of Jining Medical University, Jining, China

PRIZE COMMITTEE
Giuseppe Lauria, MD, Co-Chair, IRCCS “Carlo Besta” Neurological Institute & University of Milan, Milan, Italy
Amanda Peltier, MD, Co-Chair, Vanderbilt University Medical Center, Brentwood, TN, USA
Catharina Faber, MD, PhD, Maastricht University Medical Centre, Maastricht, Netherlands
Shawna Feely, MS, CGC, University of Iowa, Iowa City, IA, USA
Ahmet Hoke, MD, PhD, Johns Hopkins University, Baltimore, MD, USA
Ruth Huizinga, PhD, Erasmus MC, Rotterdam, Netherlands
Matilde Laura, MD, PhD, MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK
Rayaz Malik, MB, ChB, PhD, Professor of Medicine, Weill Cornell Medicine, Qatar, Doha, Qatar
Wilson Marques, Jr, MD, School of Medicine of Ribeirão Preto, Ribeirão Preto, Brazil
Susanna Park, PhD, University of Sydney, Sydney, Australia
Luis Querol, MD, PhD, Hospital de la Santa Creu i Sant Pau Barcelona, Spain
James Russell, MD, MS, University of Maryland School of Medicine, Baltimore, MD, USA
The Peripheral Nerve Society provides Annual Meetings, Teaching Courses, Guidelines, and other resources to aid in the education of members. Becoming a member of PNS means collaborating with prominent global professionals in the field to develop and provide the best treatments for people with peripheral nerve diseases and setting standards of care within the field.

Membership in the Peripheral Nerve Society is open to any professional with interest in disorders of the peripheral nervous system. Members of the Peripheral Nerve Society may join the Inflammatory Neuropathy Consortium, International Diabetes Consortium, Toxic Neuropathy Consortium and Charcot-Marie-Tooth and Related Neuropathy Consortium by request. Our membership includes clinicians, academicians, basic and clinical scientists, members of industry and representatives from neuropathy organizations. All members receive a subscription to the Journal of the Peripheral Nervous System (JPNS) and a discounted registration to our Annual Meeting.

PNS Membership Features Include:
- Subscription to Journal of the Peripheral Nervous System (JPNS)
- Discounted PNS Annual Meeting Rates
- Access to Member Directory
- Patient Information
- Networking Opportunities
- Career Planning
- Volunteer Opportunities
- Voting Rights
- PNS Members may join special interest groups upon request (IDNC, INC, TNC, or CMTR)

Visit www.PNSociety.com to join today!
The Peripheral Nerve Society (PNS) was founded in 1994 from two groups of academic investigators, Peripheral Nerve Study Group and Peripheral Neuropathy Association of America, interested in the basic biology and function of the peripheral nervous system and its application to the clinic. Their invite-only, biennial meetings involved 80-125 attendees in cloistered settings organized by shoestring and local initiative. From this, we have grown remarkably. We now have an annual meeting of over 600 people including meetings within the meeting for the special interest groups in inflammatory, diabetic, toxic, and hereditary neuropathy. With this substantial growth and the success of JPNS, the Journal of the Peripheral Nervous System, the Society continues to flourish.

The Peripheral Nerve Society provides Annual Meetings, Teaching Courses, Guidelines, and other resources to aid in the education of members. Becoming a member of PNS means collaborating with prominent global professionals in the field to develop and provide the best treatments for people with peripheral nerve diseases and setting standards of care within the field. Please participate in our future by joining the PNS, volunteering for a project aligned with your interests and sending your ideas for the future to the Executive Office, or Board member.

CONTACT US
info@PNSociety.com | www.PNSociety.com | +1-952-545-6284

PNS EXECUTIVE OFFICE STAFF

Janel Fick
Consulting Director
janelfick@PNSociety.com

Allison Kindseth, CMP
Executive Director
akindseth@PNSociety.com

Tanya Baker
Director of
Meetings & Engagement
info@PNSociety.com
PAST MEETINGS OF THE PNS
2018  Baltimore, MD, USA
2017  Sitges-Barcelona, Spain
2015  Quebec City, Canada
2013  Saint-Malo, France
2011  Potomac, MD, USA
2009  Würzburg, Germany
2007  Snowbird, UT, USA
2005  Tuscany, Italy
2003  Banff, Canada
2001  Tyrol, Austria
1999  La Jolla, CA, USA
1997  Cambridge, UK
1995  Antalya, Turkey
1994  Saint Paul, MN, USA

PAST MEETINGS OF THE PNSG
1993  Boppard, Germany
1991  Arden House, NY, USA
1989  Padua, Italy
1987  Lake Couchiching, Ontario, Canada
1985  Mürren, Switzerland
1983  Fontevraud, France
1981  Shakertown, KY, USA
1979  Wye College, Kent, UK
1977  Airlie House, VA, USA
1975  Rochester, MN, USA
1974  Carville, LA, USA

PAST MEETINGS OF THE PNAA AND PNA
1992  Rapallo, Italy
1990  Oxford, UK
1989  Maui, HI, USA
1988  Halifax, Nova Scotia, Canada
1986  Hilton Head Island, SC, USA
1985  Keystone, CO, USA
1984  Keystone, CO, USA
**SATURDAY 22 JUNE 2019**

- 9.30-11.00 Coffee & Registration  **GROUND FLOOR LOBBY**
- 11.00-19.00 Education Course  **MAESTRALE**
  - 11.00 Welcome Address  Steven Scherer
  - 11.10 The Autonomic Nervous System – A Case-based Approach to Functional Neuroanatomy  Roy Freeman
  - 11.50 A Primer on WES, GWAS and WGS as Tools for Unravelling the Genetics of Inherited Neuropathies  Marina Kennerson
  - 12.30 Imaging of PNS  Simonetta Gerevini
  - 13.10 Career Development Lunch  **GROUND FLOOR LOBBY**
  - 14.30 Mammalian Models of Neuropathy – When and How to Use Them  Steve Scherer
  - 15.10 Emerging Therapies in Autoimmune Neuropathy – Beyond IVIg  Michael Lunn
  - 15.50 Neuropathy in Resource Limited Settings, What and How to Investigate  Umapathi Thirugnanam
  - 16.30 Educational Committee and Strategies: How to Apply for Educational Event Funding  Hugh Willison and Alessandra Bolino
  - 16.45-17.15 Coffee Break & Exhibits  **MODULE 8 & 7 1ST FLOOR**
  - 17.15-18.45 Clinical Case Presentations  **MAESTRALE**
  - 19.00-23.00 Welcome Reception  **CARLO FELICE THEATRE**

**SUNDAY 23 JUNE 2019**

- 7.15-8.15 Coffee & Exhibits  **MODULE 8 & 7 1ST FLOOR**
- 7.15-8.15 Poster Viewing  **MODULE 7 2ND FLOOR**
- 7.15-8.15 Sponsored Symposia  
  - Kedrion Symposium  **AUDITORIUM**
  - Pfizer Symposium  **LEVANTE/PONENTE**
- 8.30-9.00 Peter J Dyck Lecture  **AUDITORIUM**
  Neurological Disturbances in Patients with Diabetes Beyond Peripheral Neuropathy: CNS Involvement on Multimodal Brain Imaging  Geert Jan Biessels
- 9.00-10.30 Platform Session I  **AUDITORIUM**
- 10.30-11.00 Coffee Break & Exhibits  **MODULE 8 & 7 1ST FLOOR**
- 11.00-11.30 Richard Bunge Lecture  **AUDITORIUM**
  Peripheral Nerve Homeostasis and Regeneration – Links to Disease  Alison Lloyd
  
- 11.30-12.30 Oral Poster Session I  **AUDITORIUM**
- 12.30-14.30 Lunch & Exhibits  **MODULE 8 & 7 1ST FLOOR**
- 12.30-14.30 Poster Session I  **MODULE 7 2ND FLOOR**

**14.30-18.30 Special Interest Group (SIG) Parallel Sessions**

**INFLAMMATORY NEUROPATHY CONSORTIUM (INC)  MAESTRALE**

- 14.30 Monoclonal Gammopathies of Neurological Significance  Invited Speaker: Shirley D’Sa
- 15.00 INC Project Updates
- 15.30 Oral Abstracts
- 16.00 Peripheral Neuropathy and Gastrointestinal Disease  Francisco de Assis Gondim
- 16.30 Coffee Break & Exhibits  **MODULE 8 & 7 1ST FLOOR**
- 17.00 An Overview of Inflammatory Neuropathies and Diabetes  Yusuf Rajabally
- 17.30 Oral Abstracts

**CHARCOT-MARIE-TOOTH & RELATED NEUROPATHIES CONSORTIUM (CMTR)  GRECALE**

- 14.30 Platform Presentations: Schwann Cells and Myelination
- 14.45 Oral Posters: iPSCs
- 15.00 Pathogenetic Inflammation in Models for Schwann Cell-Related Charcot-Marie-Tooth Disorders  Rudolf Martini
- 16.30 Coffee Break & Exhibits  **MODULE 8 & 7 1ST FLOOR**
- 17.00 Mechanisms of TRPV4-induced Peripheral Nerve Disease  Charlotte Sumner
- 17.30 Platform Presentations: Pathomechanisms
- 18.00 Oral Posters: Genetics and Phenotypes

**INTERNATIONAL DIABETES NEUROPATHY CONSORTIUM (IDNC)  LEVANTE/PONENTE**

- 14.30 Risk Factors for Presence and Progression of CAN in Type 2 Diabetes  Signe Toft Andersen
- 15.00 Seeing What They are Feeling – The Central Nervous System in Diabetic Peripheral Neuropathy  Dinesh Selvarajah
- 15.30 Deep Phenotyping to Explore Differences Between Painful and Painless Diabetic Neuropathy  Andreas Themistocleous
- 16.00 Sodium Channel Mutations in Small Fiber Neuropathy: Implications for Diabetic Neuropathy  Daniele Cazzato
- 16.30 Coffee Break & Exhibits  **MODULE 8 & 7 1ST FLOOR**
- 17.00 Oral Poster Session
- 17.45 Emerging Concepts in the Early Detection and Management of Diabetic Neuropathy  Invited Speaker: Dan Ziegler
- 19.00-20.00 Sponsored Symposia  
  - CSL Behring Symposium  **MAESTRALE**
  - Alnylam Symposium  **GRECALE**

**20.10-23.00 Junior Reception  **AQUARIUM**  Sponsored by Akcea**
### PROGRAM AT A GLANCE

#### MONDAY 24 JUNE 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.15-8.15</td>
<td>Coffee &amp; Exhibits</td>
<td>MODULE 8 &amp; 7 1ST FLOOR</td>
</tr>
<tr>
<td>7.15-8.15</td>
<td>Poster Viewing</td>
<td>MODULE 7 2ND FLOOR</td>
</tr>
<tr>
<td>7.15-8.15</td>
<td>Sponsored Symposia</td>
<td>Takeda Symposium AUDITORIUM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharnext Symposium LEVANTE/PONENTE</td>
</tr>
<tr>
<td>8.30-9.00</td>
<td>Arthur K Asbury Lecture</td>
<td>AUDITORIUM</td>
</tr>
<tr>
<td></td>
<td>Skin for Neurologists</td>
<td></td>
</tr>
<tr>
<td>9.00-10.30</td>
<td>Platform Session II</td>
<td>AUDITORIUM</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Coffee Break &amp; Exhibits</td>
<td>MODULE 8 &amp; 7 1ST FLOOR</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Jack Griffin Lecture</td>
<td>AUDITORIUM</td>
</tr>
<tr>
<td></td>
<td>Neuronal and Glial Mechanisms Regulating Nerve Regeneration</td>
<td></td>
</tr>
<tr>
<td>11.30-12.30</td>
<td>Oral Poster Session II</td>
<td>AUDITORIUM</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>PNS Annual General Meeting</td>
<td>(all are welcome)</td>
</tr>
<tr>
<td>13.00-14.30</td>
<td>Lunch &amp; Exhibits</td>
<td>MODULE 8 &amp; 7 1ST FLOOR</td>
</tr>
<tr>
<td>13.00-14.30</td>
<td>Poster Session II</td>
<td>MODULE 7 2ND FLOOR</td>
</tr>
<tr>
<td>14.30-18.30</td>
<td>Special Interest Group (SIG) Parallel Sessions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>INC Project Updates</td>
<td></td>
</tr>
<tr>
<td>15.00</td>
<td>Ultrasound and MRI of Peripheral Nervous System: Usefulness for Diagnosis and Therapeutic Indication</td>
<td></td>
</tr>
<tr>
<td>16.00</td>
<td>Oral Abstracts</td>
<td></td>
</tr>
<tr>
<td>16.30</td>
<td>Coffee Break &amp; Exhibits</td>
<td>MODULE 8 &amp; 7 1ST FLOOR</td>
</tr>
<tr>
<td>17.00</td>
<td>Oral Abstracts</td>
<td></td>
</tr>
<tr>
<td>17.30</td>
<td>Oral Abstracts</td>
<td></td>
</tr>
<tr>
<td>14.30</td>
<td>INC Project Updates</td>
<td></td>
</tr>
<tr>
<td>15.00</td>
<td>Ultrasound and MRI of Peripheral Nervous System: Usefulness for Diagnosis and Therapeutic Indication</td>
<td></td>
</tr>
<tr>
<td>16.00</td>
<td>Oral Abstracts</td>
<td></td>
</tr>
<tr>
<td>16.30</td>
<td>Coffee Break &amp; Exhibits</td>
<td>MODULE 8 &amp; 7 1ST FLOOR</td>
</tr>
<tr>
<td>17.00</td>
<td>Oral Abstracts</td>
<td></td>
</tr>
</tbody>
</table>

#### INFLAMMATORY NEUROPATHY CONSORTIUM (INC) MAESTRALE

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30</td>
<td>INC Project Updates</td>
</tr>
<tr>
<td>15.00</td>
<td>Ultrasound and MRI of Peripheral Nervous System: Usefulness for Diagnosis and Therapeutic Indication</td>
</tr>
<tr>
<td>16.00</td>
<td>Oral Abstracts</td>
</tr>
<tr>
<td>16.30</td>
<td>Coffee Break &amp; Exhibits</td>
</tr>
<tr>
<td>17.00</td>
<td>Oral Abstracts</td>
</tr>
<tr>
<td>17.30</td>
<td>Oral Abstracts</td>
</tr>
</tbody>
</table>

### CHARCOT-MARIE-TOOTH & RELATED NEUROPATHIES CONSORTIUM (CMTR) GRECALE

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30</td>
<td>Rare and Genetically Undiagnosed Forms of Inherited Peripheral Neuropathies</td>
</tr>
<tr>
<td>15.00</td>
<td>Platform Presentations: Genetics, Biomarkers, Amyloidosis</td>
</tr>
<tr>
<td>16.30</td>
<td>Coffee Break &amp; Exhibits</td>
</tr>
<tr>
<td>17.00</td>
<td>Measuring Disability of Infants, Children and Adults with CMT</td>
</tr>
<tr>
<td>17.30</td>
<td>Platform Presentations: Therapy</td>
</tr>
<tr>
<td>18.15</td>
<td>Oral Posters: Therapy</td>
</tr>
</tbody>
</table>

### INTERNATIONAL DIABETES NEUROPATHY CONSORTIUM (IDNC) LEVANTE/PONENTE

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30</td>
<td>Ultrasound of Peripheral Nerve in Diabetes</td>
</tr>
<tr>
<td>15.00</td>
<td>MR Neurography in Peripheral Neuropathies</td>
</tr>
<tr>
<td>15.30</td>
<td>Testing Autonomic Outcomes in Diabetic Neuropathy Research: Challenges and Advantages</td>
</tr>
</tbody>
</table>

#### TOXIC NEUROPATHY CONSORTIUM (TNC) LIBECCIO

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30</td>
<td>Summary/Update of Activities</td>
</tr>
<tr>
<td>15.00</td>
<td>The Power of Neurophysiology in Chemotherapy-Induced Peripheral Neuropathy</td>
</tr>
<tr>
<td>15.30</td>
<td>Oral Abstracts</td>
</tr>
<tr>
<td>16.30</td>
<td>Coffee Break &amp; Exhibits</td>
</tr>
<tr>
<td>17.00</td>
<td>Oral Abstracts</td>
</tr>
<tr>
<td>17.30</td>
<td>Relevance of Peripheral Neuropathy in Cancer Patients Treated with Chemotherapy</td>
</tr>
</tbody>
</table>

#### TUESDAY 25 JUNE 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.15-8.15</td>
<td>Coffee &amp; Exhibits</td>
</tr>
<tr>
<td>7.15-8.15</td>
<td>Poster Viewing</td>
</tr>
<tr>
<td>7.15-8.15</td>
<td>Sponsored Symposia</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>8.30-9.00</td>
<td>PK Thomas Lecture</td>
</tr>
<tr>
<td></td>
<td>Familial Amyloid Polyneuropathy as a Model of Medical Progress</td>
</tr>
<tr>
<td>9.00-10.30</td>
<td>Platform Session III</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Coffee Break &amp; Exhibits</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Pembroke Lecture</td>
</tr>
<tr>
<td></td>
<td>The Impact of Mitochondrial Biology on Central and Peripheral Nervous System Disorders</td>
</tr>
<tr>
<td>11.30-12.30</td>
<td>Oral Poster Session III</td>
</tr>
<tr>
<td>12.30-14.30</td>
<td>Lunch &amp; Exhibits</td>
</tr>
<tr>
<td>12.30-14.30</td>
<td>Poster Session III</td>
</tr>
<tr>
<td>14.30-16.30</td>
<td>Clinical Trial Updates</td>
</tr>
<tr>
<td>16.30-17.00</td>
<td>Coffee Break &amp; Exhibits</td>
</tr>
<tr>
<td>17.00-18.00</td>
<td>Presidential Lecture</td>
</tr>
<tr>
<td></td>
<td>Peripheral Neuropathy – 6th Edition</td>
</tr>
<tr>
<td>18.00-18.30</td>
<td>Awards &amp; Prizes</td>
</tr>
<tr>
<td>18.30-23.00</td>
<td>Closing Reception</td>
</tr>
</tbody>
</table>

2019 PNS Annual Meeting 22-25 June Genoa, Italy
GENERAL INFORMATION

REGISTRATION/HELP DESK HOURS
Saturday, 22 June  9.30-18.00
Sunday, 23 June   7.00-18.00
Monday, 24 June   7.00-18.00
Tuesday, 25 June  7.00-8.00

*The Convention Centre opens at 7.00.

REGISTRATION FEES
Registration fees include:
• Saturday Education Course
• Three full days of regular programming with special interest group afternoon parallel sessions
• Three exciting off-site receptions
• Access to sponsor marketplace and exhibitor directory
• A chance to network with friends, new and old
• Lunch and coffee breaks

BADGE
All conference participants are required to wear their name badge at all conference functions.

CERTIFICATE OF ATTENDANCE
Your certificate will be emailed to you after the meeting.

LIABILITY & INSURANCE
The organizers accept no responsibility for any injury or damage involving persons and property during the 2019 PNS Meeting.

SPEAKER READY ROOM – MODULE 9 (1ST FLOOR)
All speakers must upload presentations here, at least 60 minutes prior to the session start time.

Saturday, 22 June  9.00-19.00
Sunday, 23 June   7.00-19.30
Monday, 24 June   7.00-19.30
Tuesday, 25 June  7.00-18.00

*Note: Speaker designations are listed in the program, as submitted

WIFI INSTRUCTIONS
Complimentary WiFi is available throughout the convention centre.
Network: PNSociety2019
Password: PNSociety2019
MOBILE APP INSTRUCTIONS
Navigate the event like a pro with the PNS 2019 Annual Meeting mobile app, powered by Core-apps.com.

With the PNS 2019 Annual Meeting app, you can:
• Stay organized with up-to-the-minute speaker, exhibitor and event information
• Receive important real-time communications from PNS
• Build a personalized schedule and bookmark exhibitors
• Take notes and download event handouts and presentations
• Find attendees and connect with your colleagues through Friends
• Stay in-the-know and join in on social media with #PNS2019
• Share your event photos and experience with the Photo Gallery
• And much, much more!

DOWNLOADING THE APP IS EASY!
While on your smartphone, go to http://bit.ly/PNS2019 to be directed to the proper download version for your device.

EXHIBITION
Please be sure to visit the exhibits located in Module 7 & 8, 1st Floor. All catering service will be located here.

Exhibits open at 16.45 on Saturday 22 June.

POSTER SESSIONS
Complete abstract details and poster numbers may be found in the online supplement and the mobile app.

Poster Session I: Sunday 23 June
Room: Module 7 (2nd Floor)
Mandatory Stand by Time: 12.30-14.30

Poster Session II: Monday 24 June
Room: Module 7 (2nd Floor)
Mandatory Stand by Time: 13.00-14.30

Poster Session III: Tuesday 25 June
Room: Module 7 (2nd Floor)
Mandatory Stand by Time: 12.30-14.30

Poster Set-Up: 17.00-19.00 the evening prior to your session
Poster Dismantle: 14.30-16.00 the day of your session
We thank the generosity of our sponsors. This program would not be possible without their support.

YEAR-ROUND PARTNERS

GOLD SPONSOR

SILVER SPONSOR
ACKNOWLEDGEMENTS

BRONZE SPONSORS

ACCELERON

CANE
MEDICAL TECHNOLOGY
www.canespai.it

disarm
THERAPEUTICS

TERUMO BCT
Unlocking the Potential of Blood

PATIENT ADVOCACY GROUPS (PAGS)

Amyloidosis Research Consortium

CMT Research Foundation

EUROPEAN CMT FEDERATION

CMTA
Charcot-Marie-Tooth Association

CMT UK

EPODIN

European Cancer Patient Coalition

EUROPEAN NEURO MUSCULAR CENTRE

the FOUNDATION for PERIPHERAL NEUROPATHY®

GBS CIDP
Foundation International

HEREDITARY NEUROPATHY FOUNDATION

Please reference page 50 for the exhibitor directory.
**INDIVIDUAL MEETINGS**

**SATURDAY 22 JUNE 2019**

8.00-10.45  Inherited Neuropathy Consortium Meeting  **LIBECCIO: MODULE 9 – 3RD FLOOR**  
*This is an open meeting. All are welcome to attend.*

9.00-11.00  IGOS Meeting  **ZEFIRO: MODULE 9 – 2ND FLOOR**  
*This is a closed meeting.*

11.15-12.45  INCBase  **LIBECCIO: MODULE 9 – 3RD FLOOR**  
*This is an open meeting. All are welcome to attend.*

13.00-14.00  Patient Advocacy Group Meeting  **BORA: MODULE 9 – 1ST FLOOR**  
*This is a closed meeting.*

14.00-15.30  International Diabetes Neuropathy Consortium Board Meeting  **MARIN: MODULE 9 – 1ST FLOOR**  
*This is a closed meeting.*

14.00-16.30  CMTPeds Clinical Evaluator Meeting  **ZEFIRO: MODULE 9 – 2ND FLOOR**  
*This is a closed meeting.*

16.00-17.00  Toxic Neuropathy Consortium Board Meeting  **BORA: MODULE 9 – 1ST FLOOR**  
*This is a closed meeting.*

16.00-17.00  Charcot-Marie-Tooth & Related Neuropathies Board Meeting  **MARIN: MODULE 9 – 1ST FLOOR**  
*This is a closed meeting.*

16.00-17.00  Organizing a PNS Basic Science Consortium  **AUSTRO: MODULE 9 – 1ST FLOOR**  
*This is an open meeting. All are welcome to attend.*

17.00-18.00  CMTR Genetic Consortium Working Group  **MARIN: MODULE 9 – 1ST FLOOR**  
*This is a closed meeting.*

17.00-18.30  Vasculitic Neuropathy Study Group  **BORA: MODULE 9 – 1ST FLOOR**  
*This is a closed meeting.*

**SUNDAY 23 JUNE 2019**

10.30-11.00  Top Sponsors Meeting  **VIP ROOM*”**  
*This is a closed meeting.*

**MONDAY 24 JUNE 2019**

10.30-11.00  International Congress on Neuromuscular Diseases (ICNMD) Education Meeting  **VIP ROOM*”**  
*This is a closed meeting.*

12.00-13.00  Peripheral Nerve Society Education Committee  **VIP ROOM*”**  
*This is a closed meeting.*

**TUESDAY 25 JUNE 2019**

10.30-11.00  2020 Program Committee Meeting  **VIP ROOM*”**  
*This is a closed meeting.*

12.45-13.45  Prize Committee Meeting  **VIP ROOM*”**  
*This is a closed meeting.*

16.30-17.00  Prize Committee Meeting  **VIP ROOM*”**  
*This is a closed meeting.*

**WEDNESDAY 26 JUNE 2019**

7.30-8.30  Inflammatory Neuropathy Consortium Board Meeting  **OCEANO ROOM, NH MARINA HOTEL**  
*This is a closed meeting.*

9.00-12.00  Peripheral Nerve Society Board Meeting  **OCEANO ROOM, NH MARINA HOTEL**  
*This is a closed meeting.*

*VIP room is located in the foyer Maestrale on the ground floor, behind the escalators.*
Schedule
9.30-11.00  Coffee & Registration  GROUND FLOOR LOBBY

11.00-13.10  Education Course  MAESTRALE

Chairs: Vera Fridman, MD, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Matilde Laura, MD, PhD, MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK

11.00  Welcome Address
Steven Scherer, MD, PhD, The University of Pennsylvania, Philadelphia, PA, USA

11.10  The Autonomic Nervous System – A Case-based Approach to Functional Neuroanatomy
Roy Freeman, MBChB, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Autonomic nerve fibers are small, lightly myelinated and unmyelinated and are injured to a varying degree in most symmetrical generalized, peripheral neuropathies. While this injury is often mild or subclinical, there are a group of peripheral neuropathies in which the small or unmyelinated fibres are selectively or prominently targeted. These include the autonomic neuropathies associated with diabetes and amyloid; immune-mediated autonomic neuropathies including those associated with a paraneoplastic syndrome; inherited autonomic neuropathies; autonomic neuropathies associated with infectious diseases and toxic autonomic neuropathies. In some peripheral neuropathies, the autonomic features are the most prominent manifestation of the neuropathy, while, in others, autonomic manifestations may be less prominent compared to the sensory or motor manifestations. This lecture will adopt a case-based approach to illustrate the functional anatomy and physiology of the autonomic nervous system.

11.50  A Primer on WES, GWA and WGS as Tools for Unravelling the Genetics of Inherited Neuropathies
Marina Kennerson, PhD, ANZAC Research Institute, Sydney, Australia

Identifying new genes for inherited peripheral neuropathies (IPN) has flourished since the introduction of next generation sequencing with over 85 causative genes for CMT and related disorders reported to date. Despite this success up to 40% of families remain genetically undiagnosed. Are more genes to be identified? Can we target genes explaining the variability of the IPN phenotypes? Do non-coding mutations contribute to the unsolved IPN families? This presentation will give a primer on high throughput genomics (array genotyping, whole exome/genome sequencing) and their use with traditional gene mapping methods (positional cloning and genome wide association studies; GWAS) to further understand the genetics of IPNs. The principles of Mendelian WES variant filtering, GWAS studies to identify modifier genes and WGS analysis to identify structural variation mutations will be outlined along with the respective strengths and challenges of these approaches.
12.30 Imaging of Peripheral Nervous System
Simonetta Gerevini, MD, IRCCS Ospedale San Raffaele, Milano, Italy

Magnetic resonance imaging provides a useful tool that can be used in the diagnosis of peripheral nerve disorders. The lecture will cover what aspects can be visualized with MR imaging and describe the relationship of signal alteration and morphologic modification of nerves and muscles to disorders of the peripheral nervous system. Examples of techniques and findings in inflammatory neuropathies, genetic neuropathies and pudendal neuropathy will be provided.

13.10-14.30 Career Development Lunch  GROUND FLOOR LOBBY

14.30-16.45 Education Course continued  MAESTRALE

Chairs: Catharina Faber, MD, PhD, Maastricht University Medical Centre, Maastricht, Netherlands; Christopher Klein, MD, Mayo Clinic, Rochester, MN, USA

14.30 Mammalian Models of Neuropathy – When and How to Use Them
Steven Scherer, MD, PhD, The University of Pennsylvania, Philadelphia, PA, USA

This lecture will review animal models of neuropathy. Animals have been key for illuminating the basic biology of nerves and the pathogenesis of many kinds of neuropathies (both genetic and acquired), as well as evaluating new treatments for neuropathy. Rodents (mice and rats) have been the main models, and provide robust models of nerve injury, as well as toxic, diabetic, inflammatory, and genetic neuropathies, and as a platform for testing therapies. The ability to image living zebrafish larvae has provided insights into axonal degeneration and regeneration, and also to model toxic and genetic neuropathies. Drosophila and C. elegans have been used as models of genetic and acquired axonal neuropathies, as well as to screen for genes that play essential roles in axonal degeneration.

15.10 Emerging Therapies in Autoimmune Neuropathy – Beyond IVIg
Michael Lunn, FRCP PhD, National Hospital for Neurology, Queen Square, London, UK

The autoimmune neuropathies are a diverse group of conditions. The pathogenesis of these conditions, which is varied and complex, is becoming better understood. Steroids, PLEX and IVIg, remain the backbone of treatment for these disorders. The primary conductor for an orchestra of immunological instruments varies from disease to disease. The ability to tailor treatment to interfere with the major players will help us to reduce the burden of disability and reduce adverse effects. Treatments being made available for our use, often harvested from other specialties, are becoming useful in treating disease more specifically. Anti-CD20 drugs might be useful in antibody-mediated disease, especially those with IgG4 antibodies. Where rituximab fails, tyrosine kinase and proteasome inhibitors may be important in depleting the B-cell lineage. In T-cell mediated disease drugs from MS might be helpful, and complement inhibition has shown promise, and immunomodulation in cytokine-driven disease can effect a long term remission. This lecture will briefly cover all of these concepts and emphasize the need for collaborative and well-designed trials to prove or disprove efficacy.
Neuropathy in Resource Limited Settings, What and How to Investigate

Umapathi Thirugnanam, MBBS, MRCP, National Neuroscience Institute, Singapore, Singapore

The earth is neither flat nor round, but rather a pyramid with an apex occupied by the top 10%. At the base are 4 billion people making <8 USD/day. Business, economies and, by extrapolation, medical activities largely cater to the upper sections of the pyramid. The circumstances at the bottom are unique; and the strategies employed in the apex seldom work for the base. Using illustrative cases, this lecture will present disruptive innovations to improve diagnosis and management of peripheral neuropathy at the base of the pyramid. “These unhappy times call for the building of plans that rest upon the forgotten, ...that put faith once more in the forgotten man at the bottom of the economic pyramid” – Franklin D Roosevelt.

Educational Committee and Strategies: How to Apply for Educational Event Funding

Hugh Willison, MD, PhD, University of Glasgow, Glasgow, UK; Alessandra Bolino, PhD, IRCCS Ospedale San Raffaele, Milano, Italy

Clinical Case Presentations

17.15 A Mitochondrial ATP6 Mutation Causing a Slowly Progressive Myeloneuropathy
Tanya Bardakjian, MS, LCGC, University of Pennsylvania, Philadelphia, PA, USA

17.30 Adult Polyglucosan Body Disease Presenting with a Peripheral Neuropathy: Broadening the Clinical Spectrum
Jonathan De Winter, Antwerp University Hospital, Edegem, Belgium

17.45 Atypical Sensorimotor Neuropathy Related to Cutaneous Toxigenic Diphtheria Infection in a World Traveler
Penelope Spring, MBBS (Hons I), FRACP, PhD, Department of Neurology, Concord Repatriation General Hospital, Sydney, NSW, Australia

18.00 Mutations in SLC25A46 Cause a Spectrum of Clinical Phenotypes Including Axonal CMT with Optic Atrophy
Carolynne Doherty, MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK
18.15 Rare and Challenging Case of Guillain-Barre Syndrome Associated with Stroke Secondary to Spotted Fever
Anomali Vidanagamage, MBBS, MD, National Hospital, Colombo, Sri Lanka

18.30 PNS Toxicity Induced by Immune-checkpoint Inhibitors in Cancer Patients: Single Centre Experience
Silvia Bocci, Department of Medicine, Surgery and Neurosciences - University of Siena, Siena, Italy

19.00-23.00 Welcome Reception CARLO FELICE THEATRE

The 2019 PNS Welcome Reception will kick off at the Teatro Carlo Felice, a short walk from the Convention Centre. The theatre is the principle opera house in Genoa and is located on the Piazza De Ferrari. Guides with PNS signs will lead walking groups to the theatre from the convention centre. Please make sure to wear your badge, as this will be your ticket into the theatre. We will start the evening with opening remarks and classical music performed by members of the local music conservatory in Genoa. Cocktails and dinner will be served on the veranda starting at 20.00.

Transportation will be on your own as this is walking distance from the Convention Centre. Address: Passo Montale Eugenio, 4, 16121 Genova GE, Italy
2019 PROGRAM – SUNDAY 23 JUNE 2019

7.15-8.15 Coffee & Exhibits MODULE 8 & 7 1ST FLOOR

7.15-8.15 Poster Viewing MODULE 7 2ND FLOOR

7.15-8.15 Sponsored Symposia

**Kedrion Symposium: Possible New Therapeutic Options for IVIG in Neurology** AUDITORIUM
**Chair:** Eduardo Nobile-Orazio, MD, PhD, FAAN, Milan University, Milan, Italy; Angelo Schenone, PhD, University of Genoa, Genoa, Italy

- **7.15** Unmet Clinical Needs in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity (CIPN)
  *Andreas Argyriou, PhD, Saint Andrew’s General Hospital, Patras, Greece*

- **7.30** The Experience of IVIg intravenous immunoglobulin in the Treatment of CIPN – Preliminary Data on Animal Model
  *Guido Cavaletti, MD, University of Milano-Bicocca, Monza (I), Monza, Italy*

- **7.45** The Rational for the Use of IVIG intravenous immunoglobulin in Toxic Neuropathies
  *Nathan Staff, PhD, Mayo Clinic, Rochester, MN, USA*

- **8.00** Open Discussion (Q&A)

**Pfizer Symposium: ATTR (Amyloid Transthyretin) Amyloidosis: The Source, the Impact, the Management** LEVANTE/PONENTE
**Chairs:** Teresa Coelho, MD, Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal; Laura Obici, MD, University of Pavia, Pavia, Italy

- **7.15** Welcome and Introduction
  *Teresa Coelho, MD, Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal; Laura Obici, MD, University of Pavia, Pavia, Italy*

- **7.20** TTR in Health and Disease: What Role Does It Really Play?
  *Laura Obici, MD, University of Pavia, Pavia, Italy*

- **7.35** Clinical Follow Up of Asymptomatic Gene Carriers: Achieving the Earliest Diagnosis and Therapeutic Intervention
  *Isabel Conceição, MD, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisboa, Portugal*

- **7.50** The Patient Journey: Improving Care Through a Personalized Approach to Follow Up
  *Teresa Coelho, MD, Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal*

- **8.05** Audience Q&A
  *Teresa Coelho, MD, Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal*

- **8.15** Summary and Close
  *Teresa Coelho, MD, Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal*
8.30-9.00  
**Peter J Dyck Lecture: Neurological Disturbances in Patients with Diabetes Beyond Peripheral Neuropathy: CNS Involvement on Multimodal Brain Imaging**  
*AUDITORIUM*

*Geert Jan Biessels, MD, PhD, Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands*

**Chair:** Christopher Gibbons, MD, Beth Israel Deaconess Medical Center, Harvard Medical Center, Boston, MA, USA

Geert Jan Biessels is Professor of Neurology with a chair on Cerebrovascular disease and Cognition at the Brain Center Rudolf Magnus of the University Medical Centre Utrecht, the Netherlands. He obtained his PhD in 1997 and registered as a neurologist in 2004. His major research interest is vascular cognitive impairment (VCI), focusing on etiological research using novel MRI markers and on the role of diabetes. Using the unique properties of high field 7T-MRI his group has been able — for the first time — to detect cerebral microinfarcts in vivo and subsequently translated the technique to 3T-MRI. His team is currently assessing structure and function of the small vessels themselves, thus getting closer to the core of cerebral small vessel diseases (SVD). They also employ brain network analyses and lesion symptom mapping techniques in order to better understand cognitive impact of vascular brain injury. He is PI of the TRACE-VCI study, the META VCI map initiative and the Dutch Heart Brain Connection program. He participates in the EU-funded research program SVDs@target (https://www.svds-at-target.eu/). He is PI of two large multicentre RCTs on prevention of cognitive decline in patients with type 2 diabetes. In 2015 he received the senior investigator award of the European Stroke Organisation (ESO) and in 2016 he was appointed Fellow of the Royal College of Physicians Edinburgh in recognition of his work.

9.00-10.30  
**Platform Session I**  
*AUDITORIUM*

**Chairs:** Angelo Schenone, MD, Università degli Studi di Genova, Genoa, Italy; Jerome Devaux, PhD, Institut de Neurosciences de Montpellier, Montpellier, France

9.00  
**Biallelic Neurofascin Variants Affect Paranodal Axoglial Junctions Causing Neurodevelopmental Impairment and Central and Peripheral Demyelination**  
*Stephanie Efthymiou, UCL Queen Square Institute of Neurology, London, UK*

9.15  
**The Polygenic Architecture of Carpal Tunnel Syndrome**  
*Akira Wiberg, University of Oxford, Oxford, UK*

9.30  
**Mutations in the Small Heat Shock Proteins HSPB1 and HSPB8 Impair the Autophagic Flux**  
*Angela Sisto, Peripheral Neuropathy Research Group, University of Antwerp, Antwerp, Belgium*

9.45  
**Targeting a Core Axonal Degeneration Program to Treat Vincristine and Bortezomib-Induced Axonal Degeneration**  
*Stefanie Geisler, MD, Washington University School of Medicine in St. Louis, MO, USA*

10.00  
**Rab35 GTPase is an Inhibitor of mTORC1 and Regulates Myelination in the Peripheral Nervous System**  
*Federica Grandi, MSc, IRCCS Ospedale San Raffaele, Milano, Italy*
Dominant Mutations of a Notch Pathway Component Cause Type 2 Charcot-Marie-Tooth Disease

Jeremy Sullivan, PhD, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Richard Bunge Lecture: Peripheral Nerve Homeostasis and Regeneration – Links to Disease

Alison Lloyd, PhD, MRC Laboratory for Molecular Cell Biology, University College London, London, UK

Chair: Ahmet Hoke, MD, PhD, Johns Hopkins University, Baltimore, MD, USA

Alison Lloyd is a Professor of Cell Biology and head of the Cell Biogenesis and Tissue Regeneration research group at the MRC Laboratory for Molecular Cell Biology at University College London, UK. She studied Biochemistry for her undergraduate studies at UCL, followed by a PhD in the laboratory of Chris Marshall at the Chester Beatty Laboratories at the Institute of Cancer Research in London. This was followed by postdoctoral fellowships in Strasbourg, France and at the ICRF laboratories in Lincoln’s Inn Fields in London. In 1998, she started her laboratory at the MRC Laboratory for Molecular Cell Biology where she currently runs a research group focused on two main areas of cell biology — the control of cell biogenesis and tissue regeneration — and how these relate to tumour formation. Using the mammalian PNS as a model system, she has made ground-breaking discoveries as to how this tissue regenerates and the parallels to the development and spread of tumours— in particular to tumours that develop in patients with the familial tumour predisposition syndrome, Neurofibromatosis Type 1. She is a member of EMBO and co-chair of the UCL Cancer Domain.

Oral Poster Session I

Chairs: Oranee Sanmaneechai, MD, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Kleopas Kleopa, MD, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus

Topiramate Prevents Oxaliplatin Neurotoxicity in a Rat Model
Paola Alberti, MD, PhD, University Of Milano-Bicocca, Monza, Italy

PRDM12 is Required for Initiation of the Nociceptive Neuron Lineage During Neurogenesis
Luca Bartesaghi, PhD, Karolinska Institute, Stockholm, Sweden

MRI and Triple Stimulation Technique to Detect Brachial Plexus Abnormalities in Multifocal Motor Neuropathy
Emilien Delmont, MD, PhD, Referral Centre for Neuromuscular diseases and ALS, Hôpital La Timone, Marseille, France

Role of Supportive Diagnostic Criteria in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Data from the Italian Database
Eduardo Nobile-Orazio, MD, PhD, FAAN, Milan University, IRCCS Humanitas Clinica Institute, Milan, Italy

Guillain-Barré Syndrome following Arboviral Infection in Northeast Brazil: A Case Series
Sonja Leonhard, MD, Erasmus University Medical Center, Rotterdam, Netherlands
11.55 Unravelling the Role of Niaspan in Peripheral Nerve Regeneration
Stefano Previtali, MD, PhD, Institute of Experimental Neurology (InSpe), IRCCS Ospedale San Raffaele, Milano, Italy

12.00 Neuropathy Related Genes as Possible Modifiers of PMP22 Related Neuropathies
Anneke van der Kooi, MD, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands

12.05 Genetic and Clinical Finding in a Cohort of 341 Chinese Patients with Charcot-Marie-Tooth Disease
Ruxu Zhang, the third Xiangya Hospital, Central South University, Changsha, Hunan, China

12.10 Atypical Sensorimotor Neuropathy Related to Cutaneous Toxigenic Diphtheria Infection in a World Traveller
Penelope Spring, MBBS (Hons I), FRACP, PhD, Department of Neurology, Concord Repatriation General Hospital, Sydney, NSW, Australia

12.15 Molecular Mechanisms of Impaired Sensory Nerve Regeneration in Diabetes
Sung-Tsang Hsieh, MD, PhD, National Taiwan University Hospital, Taipei, Taiwan

12.30-14.30 Lunch & Exhibits MODULE 8 & 7 1ST FLOOR
12.30-14.30 Poster Session I MODULE 7 2ND FLOOR
14.30-18.30 SPECIAL INTEREST GROUP (SIG) PARALLEL SESSIONS

INFLAMMATORY NEUROPATHY CONSORTIUM (INC) MAESTRALE

14.30 Invited Lecture: Monoclonal Gammopathies of Neurological Significance
Shirley D’Sa, MD, FRCP, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK
Chair: Richard Lewis, MD, Cedars-Sinai, Los Angeles, CA, USA

15.00 INC Project Updates
Chair: Ken Gorson, MD, Tufts University School for Medicine, Dove, MA, USA

15.00 Updates on INC
Richard Lewis, MD, Cedars-Sinai Medical Center, Los Angeles, CA, USA

15.05 Update on INCBase
Filip Eftimov, MD, PhD, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, Netherlands; Luis Querol, MD, PhD, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain

15.25 Vasculitic Neuropathy – Registry and RODS Scale Development
Robert Hadden, BM BCh, FRCP PhD, King’s College Hospital, London, UK; Mike Collins, MD, Medical College of Wisconsin, WI, USA
15.30 **Oral Abstracts**

**Chairs:** Susumu Kusunoki, MD, Kindai University Faculty of Medicine, Osaka-Syama, Japan; Emilien Delmont, MD, PhD, Centre de Reference Maladies Neuromusculaires et SLA, Hôpital La Timone Adulte, Marseille, France

15.30  **The Association of Dengue Infection and Guillain-Barré Syndrome in Malaysia: A Case Control Study**  
Cheng-Yin Tan, MRCP, University of Malaya, Kuala Lumpur, Malaysia

15.40 **Medical Research Council (MRC) Scores as an Outcome Measure of Strength in Guillain-Barré Syndrome**  
Melissa Mandarakas, BHLthSci(Hons) MPhty PhD, Department of Neurology, Erasmus MC University Medical Center, Rotterdam, Netherlands

15.50 **Macrophage and Perisynaptic Schwann Cell Responses to Distal Nerve Injury in an AMAN Mouse Model**  
Madeleine Cunningham, MRes, PhD, University of Glasgow, Glasgow, UK

16.00 **Peripheral Neuropathy and Gastrointestinal Disease**  
Francisco de Assis Gondim, MD, MSc, PhD, FAAN, Universidade Federal do Ceará, Fortaleza, State of Ceará, Brazil  
**Chair:** Bart Jacobs, MD, PhD, Erasmus MC University Medical Center, Rotterdam, Netherlands

16.30  **Coffee Break & Exhibits**  
MODULE 8 & 7 1ST FLOOR

17.00 **An Overview of Inflammatory Neuropathies and Diabetes**  
Yusuf Rajabally, MD, FRCP, Aston University, Birmingham, UK  
**Chair:** Robert Hadden, BM, BCh, FRCP, PhD, King’s College Hospital, London, UK

17.30 **Oral Abstracts**  

**Chairs:** Thomas Harbo, MD, PhD, Aarhus University Hospital, Aarhus, Denmark; Jeffrey Allen, MD, University of Minnesota, Minneapolis, MN, USA

17.30  **Clinical and Serological Investigations in CIDP (Chronic inflammatory demyelinating polyneuropathy) Patients with Antibodies Against CNTN1/Caspr1 Complex**  
Elba Pascual-Goñi, MD, Neuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

17.40  **Treatment Status Following Corticosteroid and Immunoglobulin Treatment in the International CIDP Outcome Study (ICOS)**  
Sander Bus, MD, Amsterdam UMC, University of Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam, Netherlands
17.50 Diagnostic Delay and Work-Up of CIDP in the International CIDP Outcome Study (ICOS) cohort  
Carina Bunschoten, Erasmus MC, University Medical Center, Rotterdam, Netherlands

18.00 Pure Motor Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 17 Patients: Clinical Characteristics, Electrophysiological Study  
Antoine Pegat, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France, Lyon, France

18.10 Serum Contactin-1 Levels in Chronic Inflammatory Demyelinating Polyneuropathy – A Pilot Study  
Luuk Wieske, MD, PhD, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, Netherlands

18.20 CIDP with Antibodies to CNTN1 is Associated with HLA-DRB11 Haplotype  
Cinta Lleixà, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

14.30 Platform Presentations: Schwann Cells and Myelination

14.30 Neddylation Plays a Critical Role for Formation, Maturation and Maintenance of Schwann Cell Myelin Sheaths  
Ashwin Woodhoo, PhD, CIC bioGUNE, Ikerbasque Research Foundation, Derio, Spain

14.45 Cell Adhesion and Choline-Dependent Metabolism in PNS Myelination  
Haesun Kim, PhD, Rutgers University, Newark, NJ, USA

15.00 NRG 1 Type I Dependent Autoparacrine Stimulation of Schwann Cells in Onion Bulbs of Peripheral Neuropathies  
Ruth Stassart, MD, PhD, Department of Neuropathology University Clinic Leipzig, Department of Neurogenetics MPI of Experimental Medicine, Leipzig, Germany

15.15 Hyperglycosylation of Myelin Protein Zero: From Pathogenesis to Therapeutic Options  
Marina Grandis, MD, PhD, University of Genova, Genova, Italy, Genova, Italy

15.30 Role of the ER Stress Transcription Factor XBP1 in Charcot-Marie-Tooth Disease Type 1B  
Thierry Touvier, PhD, IRCCS Ospedale San Raffaele, Milan, Italy
15.45 **Oral Poster Session: iPSCs**

**Modeling Axonal Degeneration in CMT2E Using Human Motor Neurons**
Mario Saporta, MD, PhD, MBA, University of Miami Miller School of Medicine, Miami, FL, USA

**Modelling dHMNX and CMTX6 Using Patient Derived iPSC Motor Neurons**
Gonzalo Perez Siles, Northcott Neuroscience Laboratory (ANZAC Research Institute), Sydney Medical School (University of Sydney), Sydney, Australia

**Transplantation of Human iPSC-derived Motor Neurons for Denervation Induced Muscle Atrophy**
Robert Baloh, MD, PhD, Cedars-Sinai Medical Center, Los Angeles, CA, USA

16.00 **Pathogenetic Inflammation in Models for Schwann Cell-related Charcot-Marie-Tooth Disorders**
Rudolf Martini, PhD, University Hospital of Würzburg, Department of Neurology, Developmental Neurobiology, Würzburg, Germany
Chair: Michael Sereda, PhD, MD, Max Planck Institute for Experimental Medicine, Gottingen, Germany

16.30 **Coffee Break & Exhibits** MODULE 8 & 7 1ST FLOOR

17.00 **Mechanisms of TRPV4-induced Peripheral Nerve Disease**
Charlotte Sumner, MD, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Chair: Vincent Timmerman, MSc, PhD, University of Antwerp, Antwerpen, Belgium

17.30 **Platform Presentations: Pathomechanisms**
Chairs: Marina Grandis, MD, University of Genoa, Genoa, Italy; Gita Ramdharry, MD, Queen Square Centre for Neuromuscular Diseases, London, United Kingdom

**CaMKII Potentiates TRPV4 Mediated Calcium Influx, Resulting in Mitochondrial Axon Transport Disruption and Neurodegeneration**
Brian Woolums, Johns Hopkins University, Baltimore, MD, USA

17.45 **The Integrated Stress Response Contributes to Charcot-Marie-Tooth Type 2D Peripheral Neuropathy in Mice**
Emily Spaulding, The Jackson Laboratory, The University of Maine, Bar Harbor, ME, USA

18.00 **Oral Poster Session: Genetics & Phenotypes**

**Mutation Burden and Oligogenic Inheritance in a Large Inherited Axonopathy Cohort**
Stephan Zuchner, MD, PhD, University of Miami Miller School of Medicine, Miami, FL, USA
18.05 Mutations in Cell Adhesion Molecules Belonging to the CADM Family Cause Charcot-Marie-Tooth Disease
Adriana Rebelo, PhD, John T. Macdonald Foundation Department of Human Genetics, University of Miami Miller School of Medicine, Miami, FL, USA

18.10 Multicenter Retrospective Study in Patients with CMT1b in France: Genotype-Phenotype Correlations
Marie Subreville, CHU La Timone, Marseille, France

18.15 The Italian Registry for Charcot-Marie-Tooth Disease
Davide Pareyson, MD, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

18.20 Genotype and Phenotype in Thai Children with Charcot-Marie-Tooth Disease
Oranee Sanmaneechai, MD, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

18.25 Implications of Disease Progression During Childhood and Adolescence on Walking Speed in Charcot-Marie-Tooth Disease
Sylvia Ounpuu, MSc, Connecticut Children’s Medical Center, University of Connecticut School of Medicine, Farmington, CT, USA

INTERNATIONAL DIABETES NEUROPATHY CONSORTIUM (IDNC) LEVANTE/PONENTE
Chairs: Eva Feldman, MD, PhD, Professor of Neurology, University of Michigan, Ann Arbor, MI, USA; James Russell, MD, PhD, Professor of Neurology, University of Maryland, MD, USA

14.30 Risk Factors for Presence and Progression of CAN in Type 2 Diabetes
Signe Toft Andersen, MD, PhD, Aarhus University, Department of Public Health, Aarhus, Denmark

15.00 Seeing What They are Feeling – The Central Nervous System in Diabetic Peripheral Neuropathy
Dinesh Selvarajah, MbChB, PhD, University of Sheffield, Sheffield, UK

15.30 Deep Phenotyping to Explore Differences Between Painful and Painless Diabetic Neuropathy
Andreas Themistocleous, MBCh, PhD, FCP (SA), MRCP (UK), University of Oxford, Oxford, UK

16.00 Sodium Channel Mutations in Small Fiber Neuropathy: Implications for Diabetic Neuropathy
Daniele Cazzato, MD, IRCCS Foundation “Carlo Besta” Neurological Institute, Milan, Italy

16.30 Coffee Break & Exhibits MODULE 8 & 7 1ST FLOOR
17.00 Oral Poster Session

17.00 Sensory Neuron-derived IGF-1 Augments Neurite Outgrowth And This Autocrine/paracrine Pathway Is Suppressed in Diabetes
Reza Aghanoori, University of Manitoba, Winnipeg, Canada

17.05 Deletion of SARM1 has a Protective Effect for High-fat Diet-induced Peripheral Neuropathy and Glucose Intolerance
Ahmet Hoke, MD, PhD, Johns Hopkins University, Baltimore, MD, USA

17.10 Saturated and Monounsaturated Fatty Acids Differentially Regulate Nerve Function in Murine Models of Obesity
Amy Rumora, PhD, University of Michigan, Ann Arbor, MI, USA

17.15 Distal Symmetric Polyneuropathy is Likely the First Neurologic Complication of Obesity
Ericka Chant, MPH, University of Michigan, Ann Arbor, MI, USA

17.20 Evidence of Altered Peripheral Nerve Function in a Rodent Model of Pre-diabetes
Jakir Hossain, MD, School of Medical Sciences, UNSW, Sydney, Australia

17.25 Distribution of Obesity is a Key Differentiator of Neuropathy Status
Brian Callaghan, MD, MS, University of Michigan, Ann Arbor, MI, USA

17.30 Plasma Deoxydihydroceramides are Elevated in People with Diabetic Neuropathy and Correlate with Neuropathy Severity
Vera Fridman, MD, University of Colorado Anschutz Medical Campus Department of Neurology, Aurora, CO, USA

17.35 Early Parallel Progression Of Peripheral And Cardiac Autonomic Nerve Dysfunction In Recent-Onset Type 1 Diabetes
Gidon Bönhof, MD, German Diabetes Center, Division of Endocrinology and Diabetology at HHU, Düsseldorf, Germany

17.40 Oxidative Stress and Human Diabetic Neuropathy: Role of NADPH Oxidase 5
Faye Mendelson, University of Michigan, Ann Arbor, MI, USA
Dan Ziegler, MD, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany

19:00-20.00 Sponsored Symposia

CSL Behring Symposium: Navigating Diagnosis and Treatment Challenges in CIDP (Chronic inflammatory demyelinating polyneuropathy)

19.00 Welcome and Introduction
David Cornblath, MD, Johns Hopkins University, Baltimore, MD, USA

19.05 Impacts of Over and Under Diagnosis of CIDP
Jeffrey Allen, MD, University of Minnesota, Minneapolis, MN, USA

19.20 Finding the Best Treatment Regimen in CIDP
Pieter van Doorn, MD, PhD, Erasmus MC University, Rotterdam, Netherlands

19.35 Optimising CIDP Guidelines
Peter Van den Bergh, MD, PhD, University Hospitals St-Luc, Brussels, Belgium

19.50 Q&A
David Cornblath, MD, Johns Hopkins University, Baltimore, MD, USA

Alnylam Symposium: Untangling the Mixed Symptoms: Identifying and Treating hATTR Amyloidosis

19.00 Welcome and Introductions
Laura Obici, MD, Amyloidosis Research and Treatment Center, IRCCS, Fondazione Policlinico San Matteo, Pavia, Italy

19.05 hATTR Amyloidosis: Tracing the Threads of a Multisystem Disease
Isabel Conceição, MD, CHULN-Hospital Santa Maria, IMM, FML-Universidade de Lisboa, Lisboa, Portugal

19.20 Treat Today or Risk Tomorrow
Davide Pareyson, MD, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
Patisiran: An RNAi Therapeutic for the Treatment of the Polyneuropathy of hATTR Amyloidosis
Laura Obici, MD, Amyloidosis Research and Treatment Center, IRCCS, Fondazione Policlinico San Matteo, Pavia, Italy

19.50 Q&A
Laura Obici, MD, Amyloidosis Research and Treatment Center, IRCCS, Fondazione Policlinico San Matteo, Pavia, Italy

20.10–23.00 Junior Reception
Aquarium
Sponsored by:

All are invited, as we honor Junior and new members of the Society with a reception at the Aquarium of Genoa. The aquarium is conveniently located next to the Convention Centre. Sponsored by Akcea, this reception will feature guided exhibits, food, and beverages.

Address: Ponte Spinola, 16128 Genova GE, Italy
MONDAY PROGRAM – MONDAY 24 JUNE 2019

7.15-8.15 Coffee & Exhibits  MODULE 8 & 7 1ST FLOOR
7.15-8.15 Poster Viewing  MODULE 7 2ND FLOOR
7.15-8.15 Sponsored Symposia

**Takeda Symposium: Thirty Years of MMN Diagnosis and Treatment: What Does the Future Hold for our Patients?**  AUDITORIUM

7.15 Welcome and Introductions  
Michel Magistris, MD, Geneva University Hospital, Geneva, Switzerland

7.20 Looking Back: Our Journey with MMN  
Michel Magistris, MD, Geneva University Hospital, Geneva, Switzerland

7.35 Current Diagnostic Challenges: How Can We Improve Going Forward?  
Eduardo Nobile Orazio, MD, PhD, Milan University, ICRCCS Humanitas Clinical Institute, Milan, Italy

7.50 Looking to the Future: Advancing the Management of MMN  
Leonard H. van den Berg, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands

8.05 Q&A and Panel Discussion  
Michel Magistris, MD, Geneva University Hospital, Geneva, Switzerland;  
Eduardo Nobile Orazio, MD, PhD, Milan University, ICRCCS Humanitas Clinical Institute, Milan, Italy;  
Leonard H. van den Berg, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands

**Pharnext Symposium: Charcot-Marie-Tooth Disease: New Perspectives for Patients**  LEVANTE/PONENTE

7.15 Welcome and Introduction  
David Cornblath, MD, Johns Hopkins University, Baltimore, MD, USA

7.20 CMT1A Morbidity, Evaluation and Current Management  
Mario Saporta, MD, University of Miami, Miami, FL, USA

7.35 CMT1A: New Translational Scientific Perspectives  
Michael Sereda, MD, Max - Planck Institute for Experimental Medicine, Göttingen, Germany

7.50 CMT1A: Pipeline and Results of PXT3003 International Phase III Study  
Peter Young, MD, Institute for Sleep Medicine and Neuromuscular Disorders, Münster, Germany

8.05 Conclusions – Q/As – Closing Remarks  
David Cornblath, MD, Johns Hopkins University, Baltimore, MD, USA
Giuseppe Lauria is Professor of Neurology and director of the Department of Clinical Neurosciences at the IRCCS “Carlo Besta” Neurological Institute of Milan, Italy. He received the degree in Medicine at the University of Padova and trained as a resident in Neurology at the University of Ferrara, and was a fellow at the Department of Neuroscience at Johns Hopkins University, USA. He has pioneered the use of skin biopsy in peripheral neuropathies and neuropathic pain syndromes, contributed to the discovery of new phenotypes and gene mutations in small fibre neuropathies and participated in setting guidelines for clinical treatment of peripheral neuropathies.
Jack Griffin Lecture: Neuronal and Glial Mechanisms Regulating Nerve Regeneration  
Valeria Cavalli, PhD, Washington University in St Louis, School of Medicine, Saint Louis, MO, USA  
Chair: Robert Baloh, MD, PhD, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Dr. Cavalli’s work aims to understand the complex cascade of cellular events responsible for repairing damaged axons in peripheral nerves and to identify therapeutic targets to improve neuronal recovery following axon injury. Dr. Cavalli and her colleagues have identified several key molecular players and their roles in announcing injury, initiating a response and carrying out repair. Among them are mammalian Target of Rapamycin (mTOR), JNK-interacting protein, JIP3 and the gene regulators HDAC5 and HIF-1alpha. Dr. Cavalli earned her bachelor’s, master’s and doctoral degrees from the University of Geneva, Switzerland. During her graduate work in the lab of Dr. Jean Gruenberg in Geneva, Dr. Cavalli studied the signaling mechanisms regulating membrane trafficking in cells. She continued with postdoctoral training at the University of California, San Diego. There she joined the lab of Dr. Larry Goldstein and studied how vesicular transport impacts signaling along peripheral nerves, and, vice versa, how signaling impacts vesicular transport. In her initial studies, she focused on retrograde injury signaling, or how information about an injury is conveyed from the distantly located lesion site in the axon back to the cell body. She received a post-doctoral fellowship from the Christopher and Dana Reeve Foundation to continue her studies on injury signaling. She then joined the Washington University faculty in 2006 and is now Associate Professor in the Department of Neuroscience.

Oral Poster Session II  
Chairs: Ruth Stassart, MD, University of Leipzig, Leipzig, Germany; Chiara Briani, MD, University of Padova, Padova, Italy

11.30 - 12.30

11.30  Acute Small Fibre Neuropathy: A Neglected Condition?  
Thierry Gendre, MD, Department of Neurology, Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France

11.35  Ultrastructural Mechanisms of Macrophage-induced Demyelination in Guillain-Barré Syndrome  
Haruki Koike, Nagoya University Graduate School of Medicine, Nagoya, Japan

11.40  Antibody- and Macrophage-mediated Internodal Demyelination in CIDP: Clinical, Electrophysiological, Immunological and Pathological Correlations  
Jean-Michel Vallat, MD, National Reference Center for Rare Peripheral Neuropathies and Department of Neurology, Limoges, France

11.45  Prognostic Features for Death and Progression in Patients with POEMS Syndrome  
Stephen Keddie, MRC Centre for Neuromuscular Diseases National Hospital for Neurology and Neurosurgery, London, UK
11.50  Consequences of SAC3/FIG4 Deficiency to Phosphoinositides in Fibroblasts of Patients with CMT4J
Jun Li, MD, PhD, Wayne State University School of Medicine, Detroit, MI, USA

11.55  Adult Polyglucosan Body Disease Presenting with a Peripheral Neuropathy: Broadening the Clinical Spectrum
Jonathan De Winter, Antwerp University Hospital, Edegem, Belgium

12.00  Schwann Cell Transcript Biomarkers for Hereditary Neuropathy Skin Biopsies
John Svaren, PhD, University of Wisconsin, Madison, WI, USA

12.05  Unravelling Hallmarks of Axonal Degeneration in Charcot-Marie-Tooth Type 2 Using Induced Pluripotent Stem Cells
Jonas Van Lent, University of Antwerp, Antwerp, Belgium

12.10  Altered Nerve Triglycerides in Mouse Models of Diabetes with Neuropathy
Phillipe O’Brien, PhD, University of Michigan Medical School, Ann Arbor, MI, USA

12.15  Risk Factors for the Development of Chemotherapy Induced Peripheral Neuropathy: A Retrospective Study
Noah Kolb, MD, Robert Larner College at Medicine at the University of Vermont, Burlington, VT, USA

12.30-13.00  PNS Annual General Meeting (all are welcome) AUDITORIUM

13.00-14.30 Lunch & Exhibits MODULE 8 & 7 1ST FLOOR

13.00-14.30 Poster Session II MODULE 7 2ND FLOOR

14.30-18.30 SPECIAL INTEREST GROUP (SIG) PARALLEL SESSIONS

INFLAMMATORY NEUROPATHY CONSORTIUM (INC) MAESTRALE

14.30  INC Project Updates
Peter Van den Bergh, MD, Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium

14.30  Grant Opportunities Available through the GBS | CIDP Foundation
Lisa Butler, Executive Director of GBS/CIDP Foundation

14.32  Update on IGOS
Bart Jacobs, MD, PhD, Erasmus MC University Medical Center, Rotterdam, Netherlands

14.40  Update on Italian CIDP Databases
Eduardo Nobile-Orazio, MD, PhD, Milan University, Milan, Italy

14.50  Update on IMAGiNE Study
Marielle Prüppers, MD, Maastricht University Medical Center, Maastricht, Netherlands
15.00 Ultrasound and MRI of Peripheral Nervous System: Usefulness for Diagnosis and Therapeutic Indication  
Luca Padua, MD, PhD, Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario, A. Gemelli, IRCCS, Rome, Italy;  
Simonetta Gerevini, MD, IRCCS San Raffaele Hospital, Milano, Italy  
Chair: Stephan Goedee, MD, UMC Utrecht, Utrecht, Netherlands

16.00 Oral Abstracts  
Chairs: Emilien Delmont, MD, Hôpital La Timone Adulte, Marseille, France; Luis Querol, MD, PhD, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain

16.00 Outcomes After Single-Cycle Rituximab in Patients with Anti-MAG Polyneuropathy: An Average Eleven Years Follow-up Analysis  
Martina Garnero, Neurology Department, Ospedale Sanremo, ASL 1, Sarema, Italy

16.10 One Year Closer to Clinical Trials with a New Antigen Specific Treatment for Anti-MAG Neuropathy  
Pascal Hänggi, University of Basel, Basel, Switzerland

16.20 POEMS Syndrome: Characterization of Neuropathy and Post-Treatment Outcome in 36 Patients  
Nathalie Deschamps, CHU Bicetre, CHU Pointe à Pitre, Kremlin Bicetre, France

16.30 Coffee Break & Exhibits  
MODULE 8 & 7 1ST FLOOR

17.00 Neuropathology of Inflammatory Neuropathies  
Haruki Koike, MD, PhD, Nagoya University Graduate School of Medicine, Nagoya, Japan  
Chair: Judith Spies, PhD, Royal Prince Alfred Hospital, Camperdown, Australia

17.30 Oral Abstracts  
Chairs: Hugh Willison, MD, University of Glasgow, Glasgow, UK; Umapathi Thirugnanam, MD, National Neuroscience Institute, Singapore, Singapore

17.30 Misdiagnosis and Diagnostic Pitfalls of CIDP  
Merel Broers, Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Netherlands, Rotterdam, Netherlands

17.40 Immunomodulatory Effects of Bortezomib in Experimental Autoimmune Neuritis in Lewis Rats  
Rafael Klimas, Ruhr-University Bochum, St. Joseph University Hospital Bochum, Bochum, Germany
17.50 Difference of Clinical and Paraclinical Patterns in anti-FGFR 3-Positive Sensory Neuronopathy Cases from Brazil and Europe
Yannick Tholance, PharmD, PhD, Synaptopathies and Autoantibodies (INMG), Department of Biochemistry in University Hospital of Saint-Etienne, Saint-Etienne, France

18.00 Antibodies Directed Against Peripheral Neurons, Schwann Cells and Myelin are Frequently Found in Zika-exposed Subjects
Simon Rinaldi, MBChB, PhD, University of Oxford, Oxford, UK

18.10 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Associated with Sarcoidosis or Connective Tissue Disease
Clément Vialatte de Pé mill e, Service de neurologie CHU de Bicêtre Paris, Service de neurologie Hôpital Saint Joseph Paris, Paris, France

18.20 Holistic Characterization of the Repertoire of Targeted Autoantigens of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Christian Moritz, PhD, Institut NeuroMyoGene INSERM U1217/ CNRS UMR 5310 at the University of Lyon, Saint-Étienne, France
15.45  *Wildtype and Familial Transthyretin Amyloid Polyneuropathy: Distinct Cutaneous Biomarkers at the Distal Limb*
Gigi Ebenezer, MBBS, MD, Johns Hopkins School of Medicine, Baltimore, MD, USA

16.00  *Plasma NfL Concentration is Increased in Patients with ATTRm and Correlates with Clinical Severity Scores*
Mahima Kapoor, MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK

16.15  *Identification of TMPRSS5/Spinesin, a Novel Schwann Cell Derived Plasma Biomarker for CMT1A*
Matthew Davison, Sanofi, Framingham, MA, USA

16.30  Coffee Break & Exhibits  MODULE 8 & 7 1ST FLOOR

17.00  **Measuring Disability of Infants, Children and Adults with CMT**
Joshua Burns, PhD, The University of Sydney, Sydney, Australia
Chair: Michael Shy, MD, University of Iowa, IA, USA

17.30  **Platform Presentations: Therapy**
Chairs: Wilson Marques Jr, MD, School of Medicine of Ribeirão Preto, Ribeirão Preto, Brazil and Chiara Pisciotta, MD, PhD, University of Iowa, IA, USA

17.30  **Preclinical Gene Therapy Studies for FIG4/CMT 4J and GARS/CMT 2D**
Robert Burgess, PhD, The Jackson Laboratory, Bar Harbor, ME, USA

17.45  **Treatment of Arg98Cys MPZ Mice In Vitro and In Vivo with IFB088**
Michael Shy, MD, University of Iowa, Carver College of Medicine, Iowa City, IA, USA

18.00  **IFB-088 Treatment Improves Charcot-Marie-Tooth Type 1A Disease Phenotype of C3-PMP22 Mice**
Maurizio D’Antonio, PhD, IRCCS Ospedale San Raffaele, Milan, Italy

18.15  **Oral Posters: Therapy**

18.15  **Novel Biomarkers and Therapeutic Approaches in Charcot-Marie-Tooth Disease (CMT)**
Michael Sereda, MD, University Medical Centre Goettingen, Max-Planck-Institute of Experimental Medicine, Goettingen, Germany

18.20  **Longitudinal Assessment of Iowa FAP Cohort Treated with siRNA**
Shawna Feely, MS, CGC, University of Iowa, Iowa City, IA, USA
Patisiran, A Silencing RNA in Hereditary Transthyretin Amyloid Polyneuropathy: First Experience in Real Life
Thierry Gendre, MD, Department of Neurology, Henri Mondor Hospital, East Paris University, Créteil, France

INTERNATIONAL DIABETES NEUROPATHY CONSORTIUM (IDNC) LEVANTE/PONENTE
Chairs: Rayaz Malik, MB ChB, PhD, Professor of Medicine Weill Cornell Medicine, Qatar, Doha, Qatar; Rodica Pop Busui, MD, PhD Professor of Medicine, University of Michigan, Ann Arbor, MI, USA

14.30 Ultrasound of Peripheral Nerve in Diabetes
Stefan Meng, MD, KFJ Hospital, Vienna, Austria

15.00 MR (Magnetic resonance) Neurography in Peripheral Neuropathies
Jennifer Kollmer, MD, Heidelberg University Hospital, Department of Neuroradiology, Heidelberg, Germany

15.30 Testing Autonomic Outcomes in Diabetic Neuropathy Research: Challenges and Advantages
James Russell, MD, MS, University of Maryland, Baltimore, MD, USA

16.00 Scientific Pitfalls in Emerging Technology for Study of Neuropathy
Brian Callaghan, MD, MS, University of Michigan, Ann Arbor, MI, USA
Christopher Gibbons, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

16.30 Coffee Break & Exhibits

INTERNATIONAL DIABETES NEUROPATHY CONSORTIUM (IDNC) Continued LEVANTE/PONENTE
Chairs: Doug Wright, PhD, Kansas University Medical Center, Kansas City, KS, USA; Christopher Gibbons, MD, MMSc, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

17.00 Oral Poster Session

17.00 Tale of Two States: A Comparison Study of Baseline Health Data of Neuropathy Patients
Mamatha Pasnoor, MD, the University of Kansas Medical Center, Kansas City, KS, USA

17.05 Expression of GAP-43 in Type 2 Diabetes and IGT: A Longitudinal Study
Xin Pan, MD, Johns Hopkins School of Medicine, Baltimore, MD, USA
17.10 Genome-wide DNA Methylation Profiling Identifies Epigenetic Clues into Human Peripheral Neuropathy in Type 2 Diabetes
Stephanie Eid, MD, University of Michigan, Ann Arbor, MI, USA

17.15 Intraepidermal Nerve Fiber Regeneration is Different Between Type1 and Type2 Diabetes
Mohammad Khoshnoodi, MD, Johns Hopkins University, Baltimore, MD, USA

17.20 Epidermal Axon Changes in Patients with Prediabetes: The PACMAN Study
Dan Elliott, BS, University of Kansas Medical Center, Kansas City, KS, USA

17.30 Platform Session

17.30 Gut Microbiome and its Potential Role in Obesity-induced Allodynia
Raiza Bonomo, Loyola University Chicago, Chicago, IL, USA

17.45 A Keratinocyte-Derived Mechanism of Nicotinamide Riboside to Prevent and Reverse Diabetic Neuropathy
Cheng-Ying Ho, MD, PhD, University of Maryland School of Medicine, Baltimore, MD, USA

18.00 Mrgprd as a Potential Therapeutic Target for Painful Diabetic Neuropathy
Daniela Menichella, MD, PhD, Northwestern University, Chicago, IL, USA

18.15 Real Time Analysis of ATP Levels in DRG Neurons Derived from Normal or Diabetic Rats
Reza Aghanoori, University of Manitoba, Winnipeg, Canada

TOXIC NEUROPATHY CONSORTIUM (TNC) LIBECCIO
Chairs: Sandra Reiger, PhD, University of Miami, Coral Gables, FL, USA; Daniela Salvemini, PhD, King’s College London, University of London, London, UK

14.30 Summary/Update of Activities
Guido Cavaletti, MD, University of Milano-Bicocca, Monza (I), Milan, Italy

15.00 The Power of Neurophysiology in Chemotherapy-induced Peripheral Neuropathy
Susanna Park, PhD, University of Sydney, Sydney, Australia
15.30  Oral Abstracts

15.30  Outcome Measures in the Assessment of Chemotherapy Induced Peripheral Neuropathy – Which Tools are Most Responsive?
Tiffany Li, MBiostat BSc, University of Sydney, Sydney, Australia

15.40  Bortezomib Neuropathy: Clinical and Electrophysiological Features and its Predictive Factor
Nagaaki Katoh, Shinshu University, Matsumoto, Japan

15.50  Incidence and Characteristics of Neurological Adverse Events Secondary to Immunotherapy with Checkpoint Inhibitors
Roser Velasco, Unit of Neuro-Oncology, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain

16.00  Elevated Neurofilament Light Chain (NF-L) Levels in Pancreatic Cancer Patients with CIPN Receiving Abraxane
Catherine Stehman-Breen, MD, Disarm Therapeutics, Cambridge, MA, USA

16.10  Asymmetry in Chemotherapy-induced Peripheral Neuropathy: Differences in Patient Report and Objective Assessment
Hannah Timmins, BSc (Hons), University of Sydney, Sydney, Australia

16.30  Coffee Break & Exhibits  MODULE 8 & 7 1ST FLOOR

TOXIC NEUROPATHY CONSORTIUM (TNC) Continued  LIBECCIO
Chairs: Andreas Argyriou, MD, PhD, General Hospital of Patras, Patras, Greece; Nathan Staff, MD, PhD, Mayo Clinic, Rochester, MN, USA

17.00  Oral Abstracts

17.00  Mitochondrial Vacuolation Occurs Independent of Axon Degeneration in Paclitaxel-induced Peripheral Neuropathy
Anthony Cirrincione, BSc, University of Miami Department of Biology, Coral Gables, FL, USA

17.10  Molsidomine Provides Neuroprotection Against Vincristine-induced Peripheral Neurotoxicity
Francesco Lotti, Department of Pathology & Cell Biology, Columbia University Medical Center, New York, NY, USA

17.20  Effects of Candesartan on Mouse Models of Vincristine- and Oxaliplatin-induced Neuropathy
Hichem Bouchenaki, EA 6309 - Myelin Maintenance & Peripheral Neuropathy, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France
17.30 Relevance of Peripheral Neuropathy in Cancer Patients Treated with Chemotherapy
Alberto Sobrero, MD, Ospedale San Martino, Genova, Italy

18:00 Invited Lecture: Palliative Care in Oncology and Neuropathic Pain
Augusto Caraceni, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy

19.00-20.00 Sponsored Symposia

Grifols Symposium: Improving IVIG Dosing in Autoimmune Neuropathies
MAESTRALE

19.00 SPIN Award Ceremony

19.10 IVIG Dosing in Guillain-Barre Syndrome (GBS)
Bart Jacobs, MD, PhD, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands

19.25 IVIG Dosing in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
John England, MD, FAAN, LSU Healthcare Network Clinic, New Orleans, LA, USA

19.40 IVIG Dosing in Multifocal Motor Neuropathy (MMN)
JM. Léger, MD, National Referral Center for Rare Neuromuscular Diseases, University Hospital Pitié-Salpêtrière, Paris, France

Akcea Symposium: A ‘3D Look’ at hATTR Amyloidosis: Diagnosis, Disease Progression and Defining Real World Treatment Outcomes
GRECALE
Chair: Teresa Coelho, MD, Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal

19.00 Welcome
Teresa Coelho, MD, Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal

19.05 hATTR Amyloidosis: How Do We Rapidly Diagnose the Disease and Evaluate Polyneuropathy Impairment?
Chris Klein, MD, Mayo Clinic, Rochester, MN, USA

19.15 How Do We Define Disease Progression?
Laura Obici, MD, University of Pavia, Pavia, Italy

19.25 Can We Predict Treatment Failure?
Teresa Coelho, MD, Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal

19.35 Debate: How Do We Assess Disease Progression in the Real World?
7.15-8.15 Coffee & Exhibits MODULE 8 & 7 1ST FLOOR

7.15-8.15 Poster Viewing MODULE 7 2ND FLOOR

7.15-8.15 Sponsored Symposia

### LFB Symposium: Evidence-based Medicine and Current Advances in Multifocal Motor Neuropathy

**AUDITORIUM**

**Chairs:** Jean-Marc Léger, MD, Center for Rare Neuromuscular Diseases, Centre Hospitalo-Universitaire Pitié-Salpêtrière (or Pitié-Salpêtrière University Hospital) Paris, France; Hans Peter Hartung, PhD, Universität Dusseldorf, Dusseldorf, Germany

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.15</td>
<td>Epidemiology, Pathophysiology and New Perspectives in Multifocal Motor Neuropathy: An Update&lt;br&gt;Hans Peter Hartung, PhD, Universität Dusseldorf, Dusseldorf, Germany</td>
</tr>
<tr>
<td>7.30</td>
<td>Multifocal Motor Neuropathy: Diagnosis and Treatment Monitoring&lt;br&gt;Yusuf Rajabally, MD, PhD, Queen Elizabeth Hospital, Birmingham, UK</td>
</tr>
<tr>
<td>7.45</td>
<td>A Randomized Comparative Trial with 2 IVIGs intravenous immunoglobulins in Multifocal Motor Neuropathy: The LIME Study Results&lt;br&gt;Jean-Marc Léger, MD, Center for Rare Neuromuscular Diseases, Centre Hospitalo-Universitaire Pitié-Salpêtrière (or Pitié-Salpêtrière University Hospital) Paris, France</td>
</tr>
<tr>
<td>8.00</td>
<td>Wrap-Up</td>
</tr>
</tbody>
</table>

8.30-9.00 **PK Thomas Lecture: Familial Amyloid Polyneuropathy as a Model of Medical Progress**

**AUDITORIUM**

**David Adams, MD, PhD, APHP, Univ Paris Sud, Le Kremlin Bicêtre, France**

**Chair:** Davide Pareyson, MD, Carlo Besta Neurologic Institute, Milan, Italy

David Adams is Head of the French National Reference Centre for FAP, a position held since 2005, and has been the Coordinator of the French Network for FAP (CORNAMYL) since 2010. He was made a Professor of Neurology at the Université Paris Sud, France in 1996, and between 1996 and 2008 was Assistant Professor of the Department of Neurology at the Assistance Publique-Hôpitaux de Paris (AP-HP), Centre Hospitalier Universitaire Bicêtre, Université Paris Sud. In 2009, he became Head of the Department of Neurology at AP-HP. He is cluster Manager of Neurosciences Head and Neck since December 2016. He is now involved in research programmes of early diagnosis in sporadic cases and genetic carriers, and belongs to the European Reference Network for neuromuscular diseases ERN EURO NMD. His main areas of expertise are peripheral neuropathies, including FAP and other rare peripheral neuropathies. He has been particularly involved in the evaluation of the effects of liver transplantation on neuropathy in FAP patients in France since 1993, and the neurological risks of domino liver transplantation. He is Principal Investigator in many multicentric clinical trials for FAP. Professor Adams was an Advisory Board member for International Symposium on Familial Amyloidotic Polyneuropathy (ISFAP), the International Symposium on Liver Transplantation in Familial Amyloidotic Polyneuropathy (IS-LTFAP). He organized the First European Congress on Hereditary ATTR amyloidosis in 2015 and the First European meeting for ATTR amyloidosis for doctors and patients in 2017 in Paris. He received the 2017 PK Thomas prize from the European Academy of Neurology.
9.00-10.30 Platform Session III  AUDITORIUM

Chairs: Satoshi Kuwabara, MD, Chiba University, Chiba, Japan; Michael Shy, MD, Carver College of Medicine – University of Iowa, Iowa City, IA, USA

9.00 The Impact of Eculizumab on Neurological Improvement in Guillain–Barré Syndrome: Subanalysis of JET-GBS Study
Sonoko Misawa, Department of Neurology, Chiba University Graduate School of Medicine, Chiba, Japan

9.15 Intrinsic Growth and Plasticity Pathways Within Sensory Neurons: An Expanding List
Douglas Zochodne, MD, FRCPC, University of Alberta, Edmonton, Canada

9.30 Long-Term Efficacy and Safety of Inotersen for Hereditary Transthyretin Amyloidosis: NEURO-TTR Open-Label Extension 2-Year Update
Thomas Brannagan, MD, Columbia University Medical Center, New York, NY, USA

9.45 Autoantibodies and Pain: The Role of Leucine-Rich Glioma Inactivated 1 in Primary Sensory Neurons
John Dawes, University of Oxford, Oxford, UK

10.00 Gene Therapy for Peripheral Neuropathy CMT1A
Nicolas Tricaud, PhD, INSERM U1051, Institut des Neurosciences de Montpellier, Montpellier, France

10.15 Gene Replacement Therapy for CMT1X Neuropathy
Alexia Kagiava, The Cyprus Institute of Neurology and Genetics and Cyprus School of Molecular Medicine, Nicosia, Cyprus

10.30-11.00 Coffee Break & Exhibits  MODULE 8 & 7 1ST FLOOR

11.00-11.30 Pembroke Lecture: The Impact of Mitochondrial Biology on Central and Peripheral Nervous System Disorders  AUDITORIUM

Massimo Zeviani, MD, PhD, The Clinical School, University of Cambridge, and the MRC Mitochondrial Biology Unit, Cambridge, UK
Chair: Mary Reilly, MD, FRCP, FRCPI, UCL Institute of Neurology, London, UK

Professor Massimo Zeviani is the Director of the University of Cambridge/MRC-Mitochondrial Biology Unit in Cambridge, UK. He moved to UK from Milano, Italy, where he directed the Unit of Molecular Neurogenetics at the Fondazione Istituto Neurologico Carlo Besta. By characterizing informative patients and families affected by mitochondrial impairment, Prof Zeviani identified many disease-related genes and developed the first therapeutic approaches for mitochondrial diseases. His team has created several mouse models for the study of the molecular and cellular mechanisms of mitochondrial disorders, in addition to maintaining a clinical interest in the management and investigation of mitochondrial disease patients. His research has also provided a relevant contribution to the characterization of the role of mitochondrial dysfunction in the pathogenesis of several neurodegenerative conditions, involving the central and peripheral nervous systems.
**Oral Poster Session III**

**Chairs:** Charlotte Sumner, MD, John Hopkins Medicine, Baltimore, MD, USA; Luana Benedetti, MD, PhD, Azienda Ospedaliera Universitaria San Martino di Genova, Genova, Italy

11.30  **Bortezomib Neurotoxicity is Associated with Altered MAP2 Levels and Distribution within Human iPSC-Derived Sensory Neurons**
Nathan Staff, MD, PhD, Mayo Clinic, Rochester, MN, USA

11.35  **Rate of Progression of Utah Early Neuropathy Scale (UENS) Score in Diabetic Neuropathy**
J. Robinson Singleton, MD, University of Utah, Salt Lake City, UT, USA

11.40  **Biomarker Profiling of Neuropathic Pain in Idiopathic Peripheral Neuropathy**
Perry Van Doormaal, MD, PhD, Johns Hopkins University School of Medicine, Baltimore, MD, USA

11.45  **Influence of Body Mass Index on Disability in Children with CMT**
Gabrielle Donlevy, BAppSc, MNutrDiet, The University of Sydney, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia, Sydney, Australia

11.50  **A Mitochondrial ATP6 Mutation Causing a Slowly Progressive Myeloneuropathy**
Tanya Bardakjian, MS, LCGC, University of Pennsylvania, Philadelphia, PA, USA

11.55  **Nusinersen in Adults with Spinal Muscular Atrophy, A Single Center Experience**
Orly Moshe-Lilie, MD, Oregon Health and Science University (OHSU), Portland, OR, USA

12.00  **The Overlapping Spectrum of Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Anti-MAG Neuropathy**
Giuseppe Liberatore, Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute – IRCCS, Rozzano, Milan, Italy

12.05  **International Validation of the modified Erasmus GBS Outcome Score (mEGOS) for Guillain-Barré Syndrome**
Alex Doets, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

12.10  **Incidence of Antibodies Against the Node of Ranvier in a Prospective Cohort of 1000 CIDP**
Emilien Delmont, MD, PhD, Referral Centre for Neuromuscular Diseases and ALS, APHM, Marseille, France

12.15  **Secondary Endpoints (PATH Extension Study): Long-term Outcomes of Subcutaneous Immunoglobulin IgPro20 in CIDP Maintenance Treatment**
Ivo van Schaik, University of Amsterdam, Amsterdam, Netherlands
12.30-14.30 Lunch & Exhibits  MODULE 8 & 7 1ST FLOOR

12.30-14.30 Poster Session III  MODULE 7 2ND FLOOR

14.30-16.30 Clinical Trial Updates  AUDITORIUM

Chairs: Mary Reilly, MD, FRCP, FRCPI, UCL Institute of Neurology, London, UK; David Cornblath, MD, Johns Hopkins University, Baltimore, MD, USA

14.30 Improving Neuropathy and Mobility in Diabetes: the INMED Trial
Lindsay Zilliox, MD, MS, University of Maryland, VA Maryland Health Care System, Baltimore, MD, USA

14.43 Second IVIg Course in Guillain-Barré Syndrome Patients with Poor Prognosis (SID-GBS) Second IVIg Dose in Guillain-Barré Syndrome; Double-blind Randomized Controlled Trial
Christa Walgaard, Erasmus Medical Center, Rotterdam, Netherlands

14.56 A Dose Response RCT Of IV Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)/DRIP
Krista Kuitwaard, MD, PhD, Erasmus MC University Medical Center, Albert Schweitzer Hospital, Rotterdam, Dordrecht, Netherlands

15.09 Intravenous Immunoglobulin Overtreatment in Chronic Inflammatory Demyelinating Polyneuropathy: Double-blind Randomized Controlled Non-Inferiority Trial (IOC-TRIAL)
Max Adrichem, Amsterdam UMC - University of Amsterdam, Amsterdam, Netherlands

15.22 Restabilization after IVIg Withdrawal in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Ilse Lucke, MD, Amsterdam UMC - University of Amsterdam, Amsterdam, Netherlands

15.35 IVIg intravenous immunoglobulin Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements (GRIPPER): Study Update
Jeffrey Allen, University of Minnesota; Northwestern University, Minneapolis, MN, USA

15.48 A Randomized, Single-Blinded, Non-Inferiority Cross-Over Trial of Facilitated Subcutaneous Immunoglobulin in Multifocal Motor Neuropathy
Ali Al-Zuhairey, Department of Neurology, Neuroscience Center, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark

16.01 RECIPE: A Phase II Randomized Controlled Trial of Rituximab for Refractory CIDP with IgG4 Autoantibodies
Masahiro Lijima, MD, PhD, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan

16.14 Efficacy and Safety of PXT3003 in Patients with CMT1A: International Pivotal Phase III Trial
Shahram Attarian, MD, PHD, AP-HM et Aix Marseille Université, Marseille, France, Marseille, France
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30-17.00</td>
<td>Coffee Break &amp; Exhibits <strong>MODULE 8 &amp; 7 1ST FLOOR</strong></td>
</tr>
<tr>
<td>17.00-18.00</td>
<td><strong>Presidential Lecture: Peripheral Neuropathy – 6th Edition</strong> <strong>AUDITORIUM</strong></td>
</tr>
<tr>
<td></td>
<td>Steven Scherer, MD, PhD, <em>The University of Pennsylvania, Philadelphia, PA, USA</em></td>
</tr>
<tr>
<td></td>
<td>Chair: Pieter Van Doorn, MD, PhD, President-Elect, Erasmus MC University Medical</td>
</tr>
<tr>
<td></td>
<td>Centre, Rotterdam, Netherlands</td>
</tr>
</tbody>
</table>

Steven S. Scherer is the Ruth Wagner Van Meter and J. Ray Van Meter Professor of Neurology at the University of Pennsylvania. He received his B.S., M.D., and Ph.D. from the University of Michigan, and did an internship, neurology residency, and a fellowship at the University of Pennsylvania, before joining the faculty in 1991. For 40 years, Dr. Scherer has sought to understand the causes and treatments of peripheral neuropathies, with a focus on inherited neuropathies in his clinical work and laboratory investigations. He has served on NIH Study Sections, on the medical board of the CMT Association, and is the current president of the Peripheral Nerve Society. Dr. Scherer was the first recipient of the Alan J. Gebhart – Peripheral Nerve Society Prize for Excellence in Peripheral Nerve Research.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.00-18.30</td>
<td><strong>Awards &amp; Prizes</strong> <strong>AUDITORIUM</strong></td>
</tr>
<tr>
<td>18.30-23.00</td>
<td><strong>Closing Reception</strong> <em>(Villa Lo Zerbino)</em></td>
</tr>
</tbody>
</table>

Before you depart, please join us for a spectacular PNS Closing Reception at the beautiful Villa Lo Zerbino. Buses depart from the main entrance of the convention centre and will arrive at the villa every 30 minutes. This event should not be missed!

Address: Passo dello Zerbino, 1, 16122 Genova GE, Italy
Exhibitors
Grifols

For more than 75 years, Grifols has worked to improve the health and well being of people around the world. We are a global healthcare company that produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information and services they need to deliver expert medical care.

Alnylam Pharmaceuticals, Inc.

Alnylam is leading the translation of RNA interference into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, hepatic infectious, and CNS/ocular diseases. ONPATTRO® (patisiran) is Alnylam’s first U.S. FDA-approved RNAi therapeutic, with five investigational medicines in late-stage development. www.alnylam.com.

CSL Behring

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative biotherapies that are used to treat serious and rare conditions. Our Ig products treat debilitating diseases that range from immunologic, neurologic and vascular.

Akcea: hATTR Amyloidosis with Polyneuropathy

Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is advancing a mature pipeline of six novel drugs. Additional information about Akcea is available at www.akceatx.com.
Pfizer Inc.

TABLE #5

www.pfizer.com
info@pfizer.com

Pfizer Inc.: Working together for a healthier world®. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products.

KEDRION BIOPHARMA

TABLE #6

www.kedrion.com
www.kedrion.com/kedrion-world

KEDRION is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as hemophilia and immune system deficiencies. A primarily family-owned business, it places a high value not only on the welfare of those who benefit from its products but also on the people and communities where it operates.

LFB BIOMEDICAMENTS

TABLE #7

www.groupe-lfb.com
infomed@lfb.fr

Since it was formed in 1994, the LFB has been developing, manufacturing and marketing therapeutic proteins, for diseases that are always serious and often rare. The LFB is now one of the leading European players in biopharmaceutical, its products are aimed at health professionals, mainly hospital-based, these are plasma derived medicinal products in three major fields of therapy: immunology, haemostasis and intensive care.

PHARNEXT

TABLE #8

www.pharnext.com
contact@pharnext.com

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase 3 trial with positive topline results in CMT1A and benefits from the orphan drug status. PXT864 generated encouraging Phase 2 results in Alzheimer’s disease.
Takeda Pharmaceutical Company Limited

www.takeda.com
www.takeda.com

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology, Neuroscience and Rare Diseases and targeted R&D-investments in Plasma-Derived-Therapies and Vaccines.

Akcea: Global Medical Affairs

www.akceatx.com
info@akceatx.com

Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is advancing a mature pipeline of six novel drugs. Additional information about Akcea is available at www.akceatx.com.

Takeda – Medical Affairs

www.takeda.com
www.takeda.com

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology, Neuroscience and Rare Diseases and targeted R&D-investments in Plasma-derived Therapies and Vaccines.
About Octapharma: Octapharma is a global healthcare company developing and producing medicines based on human proteins from human plasma and human cell lines for three therapeutic areas:

- Haematology
- Immunotherap
- Critical Care

Our products are available in 115 countries and reach hundreds of thousands of patients every year.

Disarm Therapeutics is creating breakthrough disease-modifying therapeutics that prevent axonal degeneration (AxD) for patients with neurological diseases. Our goal is to stop axon loss by inhibiting SARM1, the central driver of AxD in diseases of the central and peripheral nervous systems, including Multiple Sclerosis, ALS and peripheral neuropathies.

Alnylam is leading the translation of RNA interference into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, hepatic infectious, and CNS/ocular diseases. ONPATTRO® (patisiran) is Alnylam’s first U.S. FDA-approved RNAi therapeutic, with five investigational medicines in late-stage development.

Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular technologies. We are committed to advancing apheresis through innovation in plasmapheresis using centrifugal technology. Our collaboration with customers helps enable the best possible procedures today, increase the number of clinicians who adopt these procedures, identify new uses for apheresis and develop next-generation procedures — all for the patients we ultimately serve.
UCB

UCB is a global biopharmaceutical company with a focus on neurology and immunology. Our medicines treat thousands of people around the world. We engage with patients, families and healthcare professionals to address unmet needs. We are around 7500 people in all four corners of the globe, inspired by patients and driven by science.

GBS|CIDP Foundation International

The GBS|CIDP Foundation International is a global nonprofit organization supporting individuals and their families affected by Guillain-Barre Syndrome, chronic demyelinating polyneuropathy and related conditions through a commitment to provide support and education, fund research and to advocate for the patient voice.

European Cancer Patient Coalition

European Cancer Patient Coalition (ECPC) is the largest European cancer patients’ umbrella organisation. Established in 2003 with over 450 members, the ECPC is the voice of the European cancer community, uniquely representing the interests of all cancer patient groups, from the most common to the rarest forms of cancer.

Hereditary Neuropathy Foundation

HNF, a CMT advocacy and research organization leads efforts in the development of breakthrough treatments with its many stakeholder partnerships. With a commitment to patient-focused research, HNF has been instrumental in hosting the groundbreaking FDA EI-PFDD meeting in 2018 and in the development of the first potential drug for CMT1A.
ACMT-Rete per la Malattia di Charcot-Marie-Tooth

**TABLE #21**

www.acmt-rete.it
acmt-rete@acmt-rete.it

ACMT-Rete is an Italian not-for-profit organization with the following aims:
- Promoting information projects in order to increase awareness on the treatment of CMT disease and similar syndromes;
- Encouraging the creation of centers for diagnosis and treatment working in strict collaboration;
- Developing a relationship network across people suffering from Charcot-Marie-Tooth’s disease.

Amyloidosis Research Consortium

**TABLE #22**

www.arci.org
arc@arci.org

The Amyloidosis Research Consortium (ARC) is a global organization founded in 2015 dedicated to changing the way research is being done and focusing on what will have the greatest impact on improving the lives of patients. We forge collaborations across industry, academia and regulatory to improve and accelerate research.

CMT Research Foundation

**TABLE #23**

cmtrf.org
info@cmtrf.org

Focused on development of treatments and cures for CMT, The CMT Research Foundation funds the most promising, high-impact translational research by developing strategic alliances with academic and industry stakeholders. On a rolling basis, The CMT Research Foundation accepts innovative proposals which solve missing links and advances current research.

European CMT Federation

**TABLE #24**

ecmtf.org
info@ecmtf.org

The Federation of European Associations of patients suffering from de Charcot-Marie-tooth disease
The Charcot-Marie-Tooth Association (CMTA) is dedicated to finding treatments and a cure for CMT, and to improving the quality of life for everyone living with the disease. The CMTA's Strategy to Accelerate Research (STAR) brings top researchers together with pharmaceutical and biotechnology partners to accelerate scientific breakthroughs. STAR has one goal: to accelerate the development of treatments for CMT. Both research and treatment happen at the two dozen CMTA-supported Centers of Excellence at top-flight medical institutions nationwide. The CMTA also offers a number of community programs, including more than 70 local branches nationwide; Camp Footprint, the nation’s only camp exclusively for kids with CMT; and Patient/Family conferences, where patients can meet the researchers and clinicians working on their behalf. To learn more about the CMTA, please visit www.cmtausa.org.

CMT United Kingdom (CMT UK) is the charity working to support those who are affected by Charcot-Marie-Tooth Disease. We offer support to people who have Charcot-Marie-Tooth Disease and their careers, Initiate, co-ordinate, promote and support research into CMT and its effects. Stimulate medical education on the subject of CMT. Spread awareness of the condition to health professionals and the general public.

EPODIN / European Patient Organisation for Dysimmune and Inflammatory Neuropathies (EPODIN) is an International Non-Governmental Organization, composed of European patients’ organizations involved in the field of rare immune-mediated peripheral-neuropathies (IMN). The contribution of EPODIN aims, by mobilizing and strengthening the patient’s voice, to give each European citizen living with IMN the opportunity to reduce the burden and inequalities due to the disease.
The European Neuromuscular Centre (ENMC) was founded 25 years ago, with the aim to bring leading researchers, clinicians and patient representatives from all over the world together via the well-known platform of ENMC workshops. Topics of the workshops vary from diagnostic tools, outcome measures, clinical trial readiness, to care management for all neuromuscular conditions.

The Foundation for Peripheral Neuropathy is a public, 501c(3) charity organization committed to fostering collaboration among today’s most gifted and dedicated neuroscientists and physicians. The Foundation’s mission is to dramatically improve the lives of people living with peripheral neuropathy by advancing research, raising awareness, accelerating a cure, funding efforts of leading scientists and serving as the premier resource of information for patients, their families and healthcare providers.
Takeda: a trusted partner in peripheral neuropathies

Takeda has a robust foundation of experience in treating rare immunological conditions. Built on this experience, the future of Takeda is dedicated to treatments for patients with selective peripheral neuropathies.

Join our PNS symposium at 7:15 – 8:15 am on Monday 24 June in the Main Auditorium

Thirty years of MMN diagnosis and treatment: What does the future hold for our patients?

With presentations from:

Prof. Leonard H. van den Berg  
University Medical Center Utrecht  
The Netherlands

Prof. Eduardo Nobile-Orazio  
University of Milan  
Italy

Prof. Michel Magistris  
Geneva University Hospitals  
Switzerland
**ATTR POLYNEUROPATHY:**
The source, the impact, the management

Sunday 23<sup>rd</sup> June 2019  
07:15–08:15 AM  
Levante/Ponente  
Centro Congressi, Porto Antico di Genova, Genoa, Italy  
Co-Chair: Dr Teresa Coelho (Portugal)  
Co-Chair: Dr Laura Obici (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15–07:20</td>
<td>Welcome and introduction</td>
<td>Dr Teresa Coelho (Portugal) and Dr Laura Obici (Italy)</td>
</tr>
<tr>
<td>07:20–07:35</td>
<td><strong>TTR in health and disease: What role does it really play?</strong></td>
<td>Dr Laura Obici (Italy)</td>
</tr>
<tr>
<td>07:35–07:50</td>
<td><strong>Clinical follow up of asymptomatic gene carriers:</strong> Achieving the earliest diagnosis and therapeutic intervention</td>
<td>Dr Isabel Conceição (Portugal)</td>
</tr>
<tr>
<td>07:50–08:05</td>
<td><strong>The patient journey: Improving care through a personalised approach to follow up</strong></td>
<td>Dr Teresa Coelho (Portugal)</td>
</tr>
</tbody>
</table>
| 08:05–08:10   | **Audience Q&A**                                                        | All faculty  
Moderated by Co-Chairs                                                                    |
| 08:10–08:15   | **Summary and close**                                                   | Dr Teresa Coelho (Portugal) and Dr Laura Obici (Italy)                                     |
Pushing the boundaries of science

Everything we do starts with one simple question:

“how will this make a difference to the lives of patients?”

UCB has a passionate, long-term commitment to help patients and families living with severe diseases lead normal, everyday lives.

Our ambition is to offer them innovative new medicines and ground-breaking solutions in two main therapeutic areas: neurology and immunology. We foster cutting-edge scientific research that is guided by patients’ needs.
A visionary concept in drug development

PLEOTHERAPY™
A new approach for developing innovative drug combinations based on big-data genomics and artificial intelligence

www.pharnext.com
OVERVIEW

Join Professor Teresa Coelho and our expert faculty panel for this interactive debate-style symposium which will seek to answer key clinical questions around hATTR amyloidosis and the critical role peripheral nerve specialists play in the management of these patients:

• How do we rapidly diagnose the disease and evaluate polyneuropathy impairment?
• What role does genetic testing have in screening patients in high-risk populations?
• How do we define disease progression?
• Can we predict treatment failure?
• How do we assess disease progression in the real world?
ONPATTRO® (patisiran) is indicated for the treatment of hATTR amyloidosis in adult patients with Stage 1 or Stage 2 polyneuropathy¹

Through a natural process called RNAi, patisiran causes the catalytic degradation of TTR mRNA in the liver, resulting in a reduction of serum TTR protein¹

56.1% of ONPATTRO®-treated patients versus 3.9% of placebo-treated patients experienced improvements in mNIS+7a (p<0.001)¹b

At 18 months, a benefit with ONPATTRO® to placebo was observed across all domains of Norfolk QoL-DN¹

To learn more please visit the Alnylam booth

Please request the full Summary of Product Characteristics at the Alnylam booth for further details

ONPATTRO® is currently not commercially available in Italy, pending pricing and reimbursement approvals

¹Composite measure of motor, sensory, and autonomic polyneuropathy

²In a threshold analysis of mNIS+7 (change from baseline of <0 points)

ATTR, TTR amyloidosis; hATTR, hereditary ATTR (hATTR) amyloidosis; mNIS+7, modified NIS plus 7; mRNA, messenger RNA; NIS, neuropathy impairment score; QoL-DN, Quality of Life-Diabetic Neuropathy; RNA, ribonucleic acid; RNAi, RNA interference; TTR, transthyretin

Developed and produced by Alnylam Pharmaceuticals

Reference:

1. Alnylam Pharmaceuticals. ONPATTRO®. EU Summary of Product Characteristics, 2018

Alnylam is a trademark of Alnylam Pharmaceuticals, Inc.
© 2019 Alnylam Pharmaceuticals, Inc. All rights reserved. 04.2019 TTR02-ITA-00003-032019 (EU/1/18/1320/001) Advertising material submitted to AIFA on 17/04/2019

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system, by contacting the Rete Nazionale di Farmacovigilanza dell’ Agenzia Italiana del Farmaco (www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa)
For chronic inflammatory demyelinating polyneuropathy (CIDP)

FOLLOW THE PATH
The next step in CIDP treatment

Visit CSL Behring at table #3

“Follow the PATH” to the CSL Behring table to learn about:

- PATH, the largest CIDP clinical trial
- The first and only subcutaneous Ig (SCIG) for maintenance treatment in CIDP
- CSL Behring and the 100+ years of experience developing and delivering plasma-derived products

Attend our Symposium:

Time: Sunday, 23 June 2019 at 19:00
Location: Maestrale Auditorium
Speakers: David Cornblath, MD (Chair)
Jeffrey Allen, MD
Pieter van Doorn, MD, PhD
Peter Van den Bergh, MD, PhD
Theme: Navigating diagnosis and treatment challenges in CIDP

CIDP indication currently not reimbursed in Italy for Hizentra. Please see Italian SPC available at table.
CARING FOR PEOPLE

For more than 75 years, Grifols has worked to improve the health and well-being of people around the world. We are committed to producing essential plasma-derived medicines for patients and to providing hospitals, pharmacies, and healthcare professionals with the tools, information, and services they need to deliver expert medical care.
Epidemiology, pathophysiology and new perspectives in Multifocal Motor Neuropathy: an update
Pr Hans Peter Hartung – Germany (15’)

Multifocal Motor Neuropathy: diagnosis and treatment monitoring
Pr Yusuf Rajabally – UK (15’)

A randomized comparative trial with 2 IVIGs in Multifocal Motor Neuropathy: the LIME study results
Dr Jean-Marc Léger – France (15’)

5’ wrap up
Intravenous human normal immunoglobulin (IVIG) 1,2

octagam® 5% 1,2
50 mg/mL solution for infusion

octagam® 10% 1,2
100 mg/mL solution for infusion

panzyga® 1,2
100 mg/mL solution for infusion

Immunomodulation therapy in CIDP & GBS 1,2

This medicinal product is subject to additional monitoring. The Summary of Product Characteristics of octagam®5%, octagam®10% and panzyga® are available on request at the booth. The products are licensed in Europe for immunomodulation in adults, and children and adolescents (0-18 years) in GBS (indicated as “2”), whereas octagam®9% and octagam®10% are also licensed for CIDP (indicated as “1”). In Italy, octagam®10% is licensed as Gamten® and panzyga® as Globiga®.

Abbreviations: CIDP, chronic inflammatory demyelinating polyneuropathy; GBS, Guillain-Barré syndrome.

EXPLORE GENOA

GENOA MAP
Stop by the Convention Visitors Bureau desk in the Ground Floor Lobby to pick up a map of the local area including locations for conference events and metro stations.

Desk Hours:
Saturday, 22 June 9.00 – 18.00
Sunday, 23 June 9.00 – 18.00
Monday, 24 June 9.00 – 18.00
Tuesday, 25 June 9.00 – 18.00

ONLINE
To discover more about Genoa, local attractions and events happening during your stay, go to www.visitgenoa.it/en.
2020 ANNUAL MEETING
27-30 JUNE  INTERCONTINENTAL MIAMI